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The role of NBS1 in the insulin-like growth factor-1 signaling 
 
ABSTRACT 
 
The Nbs1 protein (nibrin, p95) is a member of the DNA repair/checkpoint complex 
Mre11/Rad50/Nbs1 (MRN), which plays a critical role in the cellular responses to DNA 
damage, cell cycle checkpoints, and telomere and genome stability. Many transgenic models 
in mice and clinical symptoms of NBS patients have clearly shown that Nbs1 exerts 
pleiotropic actions in growth and development of mammals. However, the molecular role of 
Nbs1 in mitogenic signaling pathways which could explain the growth retardation, 
developmental defects and impaired proliferation capacity of NBS patient cells has not been 
demonstrated, so far.  
This study shows that after repression of endogenous Nbs1 levels using short interference 
RNA, hTERT-immortalized RPE cells exhibit decreased proliferation ability and poor 
response to IGF-1 stimulation. After release from G1 arrest, NBS1 siRNA-transfected cells 
display disturbances in periodical oscillations of cyclin E and A, and delayed cell cycle 
progression. Remarkably, lower phosphorylation levels of c-Raf, and diminished activity of 
ERK1/2 in response to IGF-1 suggest a link between NBS1, IGF-1 signaling, and 
Ras/Raf/MEK/ERK cascade. The functional relevance of NBS1 in mitogenic signaling and 
initiation of cell cycle progression are demonstrated in NBS1 siRNA-transfected cells where 
IGF-1 has a limited capacity to induce expressions of FOS and CCND1.  The impact of NBS1 
on the IGF-1 signaling cascade is finally identified by the reduction of IGF1R, SOS1 and 
SOS2 expression in NBS1 siRNA-transfected cells. The disturbed IGF-1 signaling, a 
consequence of diminished expression of the key components of the cascade, results in a 
failure of IGF-1 to rescue NBS1 siRNA-transfected cells from gamma radiation-induced cell 
death.  
In conclusion, this study provides the first evidence that, by modulating the IGF-1 signaling 
cascade, NBS1 has a functional role in the promotion of cell cycle progression, cell 
proliferation, and cellular radio-resistance in addition to its well known function for proper 
DNA double strand break signaling. 
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1. INTRODUCTION 
 
1.1 Statement and significance of the problem 
 
The Nbs1 protein plays an important role in cellular responses related to DNA damage, such 
as cell cycle control, DNA double strand break (DSB) repair, maintenance of telomeres and 
genomic stability [1-4]. Mutations of the gene NBS1 encoding Nbs1 may cause the 
Nijmegen breakage syndrome (NBS), which is characterized by microcephaly, 
developmental defects, growth retardation, immunodeficiency, radiation hypersensitivity, 
and increased cancer risk [4,5]. Based on the clinical symptoms of NBS patients and cellular 
defects of NBS cells, the functional roles of NBS1 in DNA damage repair processes and cell 
cycle checkpoint signaling have been investigated intensively. However, the molecular role 
of Nbs1 in mitogenic signaling pathways which could explain growth retardation and 
developmental defects of NBS patients and impaired proliferation capacity of NBS patient 
cells has not been demonstrated.  
 
Insulin like growth factor 1 (IGF-1) is a potent mitogenic factor which plays a critical role in 
both fetal and postnatal growth in mammals, and the IGF-1 signaling system also controls 
tissue homeostasis throughout life via regulation of cell proliferation and apoptosis [6-10]. 
Mutations in the IGF-1 gene result in severe pre- and post-natal growth and developmental 
defects and mental retardation in humans [11]. Decreased IGF-1 signaling is associated with 
increased incidence of cancer and enhanced cellular radio-sensitivity [12], while increased 
IGF-1 signaling stimulates proliferation, promotes metastasis, and causes radio-resistance of 
cancer cells [13,14]. IGF-1 has been shown to regulate both expression and activity of 
various molecules involved in cell cycle progression especially during the G1 phase, like 
cyclin D1 and cyclin E [15] . Furthermore, the IGF-1 signaling system is reported to confer 
a strong anti-apoptotic activity in response to a variety of stimuli inducing cell death, 
including ionizing radiation [16].  
 
Deregulation of NBS1 and IGF-1 system share some common phenotypic characteristics, 
therefore it can be expected that there are some functional links between them. Elucidation 
of the link between Nbs1 and IGF-1 is an ideal research topic for providing further aspects 
to functions of Nbs1 besides its roles in DNA damage repair processes and cell cycle
Introduction 
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 checkpoint signaling. This could improve the understanding of the observed phenotypes in 
cell lines mutated in NBS1 and of the clinical symptoms of NBS patients and give a new 
molecular explanation for the impaired proliferation capacity and increased radio-sensitivity 
of NBS cells.  
Introduction 
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1.2 Goal of the study 
 
As mentioned before, deregulation of the IGF-1 system or NBS1-dependent processes result 
in an impaired cell proliferation. Therefore, the goal of this study is to elucidate the 
functional roles of NBS1 in the regulation of cell cycle progression, cell proliferation, and 
cell survival. 
 
For this purpose, the RNA interference technology was exploited to specifically repress 
NBS1 levels in the telomerase-immortalized human retinal pigment epithelial (hTERT-RPE) 
cell line. The impact of NBS1 on cell cycle regulation was determined by analyzing the cell 
cycle distribution, the expression pattern of cell cycle-specific cyclins, and the cellular 
proliferation rate of NBS1 siRNA-transfected cells. 
 
The functional relevance of NBS1 in mitogenic signaling, especially mitogen-stimulated cell 
cycle transition at G1 to S phase was evaluated. In this study, the influence of NBS1 on 
IGF-1-stimulated signaling was analyzed. This is the major pathway which is responsible for 
initiating cell proliferation by controlling the cell cycle during G1 to S phase, and signal 
transduction via this pathway was studied in NBS1-transfected cells. Furthermore, the 
influence of NBS1 on the expression levels of IGF1R, SOS1, and SOS2, the key molecules 
for initiating the IGF-1 response were determined. 
 
In order to link the data observed from the studies above to the enhanced radio-sensitivity of 
NBS cells, which is the most prominent phenotype of these cells, the impact of IGF-1-
induced signaling on the cell survival after irradiation was analyzed in NBS1-transfected 
cells. 
 
Summarizing, acquired data in this study established a link between the IGF-1-mediated 
proliferation and the impaired proliferation of NBS cells. Additionally, experiments were 
designed to give an explanation for the severe radio-sensitivity caused by NBS1 deficiencies 
by a further mechanism besides impaired DSB-induced signaling or enhanced radiation-
induced apoptosis. 
Introduction 
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1.3 Review of literature 
 
1.3.1 Nijmegen breakage syndrome  
 
1.3.1.1 Nijmegen breakage syndrome 1 gene and its product  
 
The Nijmegen breakage syndrome 1 protein (Nbs1), also called nibrin and p95, is a 754 
amino acid protein with a predicted molecular weight of 95 kD. Nbs1 was identified in 1998 
as the product of the NBS1 gene which is located on the long arm of chromosome 8 (8q21) 
[1,2,4]. The entire gene consists of 16 exons and spans over 51 kb of DNA. Biallelic 
(homozygous or compound heterozygous) mutations in the NBS1 gene may cause the 
Nijmegen Breakage Syndrome (NBS) [5].  
 
More than 90% of all NBS patients are homozygous for a 5 bp truncating mutation, 657del5 
[4]. The NBS cells harbouring this mutation contain a predicted 26 kD amino-terminal 
truncated protein, Nbs1p26, and a 70 kD protein, Nbs1p70, lacking the native N-terminal [17]. 
The Nbs1p26 results from a frame shift at the codon encoding Nbs1 amino acid 218 and 
premature termination of translation at codon 219. The Nbs1p70 is produced by internal 
translation initiation within the NBS1 mRNA using an alternative open reading frame 
generated by the 657del5 frame shift [4,17]. Nbs1p26 is actually observed in cells from 
patients and heterozygotes with the 657del5 mutation, whereas Nbs1p70 is of much lower 
abundance and so far only observed in EBV-transformed lymphoblastoid cells [17].         
The NBS1 657del5 mutation is a hypomorphic defect because the truncated protein products 
seem to be partially functional which diminishes the severity of the NBS phenotype [17].  
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1.3.1.2 The structure and function of Nbs1 
Nbs1 contains three functional regions: the N-terminus (1-196 a.a.), a central region (278-
343 a.a.), and the C-terminus (682-746 a.a.). The N-terminal region has two functional 
domains, a forkhead-associated (FHA) domain (24-108 a.a.) and a breast cancer carboxy-
terminal (BRCT) domain (108-196 a.a.) [1,2,4,18] (see Fig. 1). FHA and BRCT domains are 
widely conserved in eukaryotic nuclear proteins that are related to cell cycle check points or 
DNA repair [19]. The FHA domain is believed to be a phospho-specific protein-protein 
interaction motif that recognizes phosphorylation of the target protein [20]. The FHA/BRCT 
domain directly binds to phosphorylated histone H2AX which occurs near sites of DNA 
strand breakage and recruits the Mre11/Rad50/Nbs1 (MRN) complex to the vicinity of sites 
of DSBs [21]. Cells derived from NBS patients that express Nbs1 truncated proteins with     
a mutation in either of these domains manifest a defect in ionizing radiation-induced MRN 
foci formation and show hypersensitivity to ionizing radiation, suggesting a role of both 
domains for cell survival after exposure to ionizing radiation [22,23].   
 
 
 
 
                                                                                
         
     modified from Tauchi 2002 [24] and Lee 2006 [25]  
Figure 1. Scheme of the functional domains of Nbs1. The forkhead-associated (FHA) and 
Brca1 COOH-terminus (BRCT) domains in the NH2-terminal region bind to γ-H2AX and are 
required for ionizing radiation (IR)-induced foci formation and radiation resistance. 
Phosphorylation of Ser278 and Ser343 by ataxia telangiectasia mutated protein (ATM) is 
essential for activation of the S phase checkpoint. The nuclear localization signal (NLS) is used 
to target the protein to the nucleus. The Mre11-binding domain is responsible for binding to 
Mre11 during formation of the Mre11/Rad50/Nbs1 (MRN) complex. The ATM-binding domain 
at the COOH-terminus binds to ATM and mediates recruitment of ATM to ionizing radiation-
induced foci. 
Foci formation
Radiation resistance
γ-H2AX binding
S phase checkpoint MRN complex 
formation
Radiation resistance
Cell cycle checkpoint
Recruitment 
of ATM to 
ionizing 
radiation-
induced foci
PP
FHA BRCT Mre11
Ser 278 Ser 343
NLS NLSNLS
ATM 
binding
754
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Several SQ motifs, consensus sequences of phosphorylation by ATM or ATR (an ATM and 
Rad3-related) kinase, are found in the central region of Nbs1. In particular, the serine 
residues at 278 and 343 are phosphorylated by ATM in response to radiation and these 
phosphorylations confer functions in signal transduction for damage response to Nbs1 [26-
29]. Cells expressing Nbs1 proteins with mutations at these phosphorylation sites exhibit 
defective S phase checkpoint control, suggesting that Nbs1 phosphorylation by ATM is 
required at least for activation of the S phase checkpoint in response to ionizing radiation 
[30,31]. A defect in the S phase checkpoint was early recognized in NBS cells as radio-
resistant DNA synthesis (RDS) which is identified as a failure to halt DNA synthesis after 
DNA has been damaged by ionizing radiation [19]. 
The C-terminal region of Nbs1 contains three potential nuclear localization signals (NLSs) 
at amino acid residues 461–467, 590–594, and 751–754 which are used to target the protein 
to the nucleus, and it has binding domains for Mre11 and ATM. The Mre11-binding domain 
has been localized to amino acids 682–693. Deletion of this region of the Nbs1 protein 
results in  cellular phenotypes including defects in MRN foci formation, radiation 
hypersensitivity and the impairment of checkpoint control [23,32]. The extreme C-terminal 
region of Nbs1 at amino acids residues 734–754 mediates the interaction of Nbs1 with ATM 
and the recruitment of ATM to sites of DNA damage, thereby promoting ATM-dependent 
signaling [33].  
 
Nbs1 is the regulatory subunit of the MRN complex which plays important roles in the 
processes of telomere maintenance, recognition and repair of DSBs, and transduction of 
damage-response signals to the cell cycle check point apparatus [34]. The primary function 
of the MRN complex is to sense DSBs and then to amplify the initial signal and convey it to 
downstream effectors, such as ATM, p53, SMC1 and BRCA1, that regulate cell cycle 
checkpoints and DNA repair [5,19,34-36].  
 
The MRN complex appears as a bipolar structure with a global head and two long tails [37] 
(see Fig. 2). The head consists of two Rad50 ABC ATPase domains, along with the Mre11 
dimer [38,39]. The precise location of Nbs1 has not been revealed, however mutagenesis 
and biophysical data suggest that it binds to the Mre112:Rad502 head, possibly forming        
a hexameric Mre112/Rad502/Nbs12 complex [40]. Rad50 contains walker A and B motives 
that are required for nucleotide binding and are separated by two coiled-coil regions that are 
Introduction 
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required for intramolecular interactions [37,41]. Mre11 has a single- and double-stranded 
(ds) DNA endonuclease, as well as a 3′–5′ dsDNA exonuclease function [42]. Mre11/Rad50 
has a structural role in bridging DNA ends through the coiled-coil regions of Rad50 where 
Mre11 can process these ends by its nuclease activity [43]. Up to date, there is no evidence 
for any enzymatic activity of Nbs1, but rather, it serves as a molecular chaperone, guiding 
the MRN complex to the nucleus and targeting the complex to the sites of DSBs following 
irradiation [32,44]. 
 
 
 
 
 
 
 
 
 
 
                                                                                                    
                                                                                            modified from van den Bosch [45] 
 
Figure 2. Scheme of the structural model of the MRN complex architecture. Mre11 (brown) 
binds to the coiled-coil domains of Rad50, adjacent to the ABC domains (green) of Rad50. The 
Rad50 antiparallel coiled-coil domains protrude from the ABC domains. The apex of the coiled-
coil domains contains the zinc hook, implicated in metal-mediated intramolecular or 
intermolecular joining of MRN complex via the Rad50 coiled-coils. The precise location of 
Nbs1 has not been revealed. 
 
 
1.3.1.3 Growth retardation and developmental defect in NBS 
 
Growth retardation and developmental defects are the main clinical manifestations of NBS. 
Children with NBS, in spite of being born at term, are characterized by a significantly lower 
birth weight and head circumference in comparison with sex-matched controls, as well as 
lower birth length and chest circumference [46]. Microcephaly, specifically head 
circumference below the third percentile, is the most striking symptom of NBS. Most 
patients are born with microcephaly, but in individuals who were born with a head 
 
coiled-coilcoiled-coil
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circumference within the reference range, progressive and severe microcephaly develops 
during a few months of life [47]. The craniofacial characteristics of NBS patients are 
observed as a sloping forehead and receding mandible, a prominent mid-face with               
a relatively long nose, and relatively large ears [5,48]. Short structure is apparent after 
approximately 2-years of age, and it is a result of trunk shortening [5]. The poor 
development of secondary sex characteristics as the results of lack of genital organs and 
breasts are usually observed in NBS female patients who reach pubertal age [49]. Several 
studies in mice models strongly support the clinical symptoms of NBS patients. Mice with 
targeted hypomorphic mutations of NBS1 show growth retardation and impaired cellular 
proliferation. Lymphoid and germ cell development are especially disturbed [50]. NBS1 
null mice lead to early embryonic lethality in utero which is associated with poorly 
developed embryonic and extraembryonic tissues [51]. The clinical symptoms in NBS 
patients and mouse models of NBS suggest essential functions of Nbs1 in cell proliferation 
and normal growth and development of mammals.   
 
 
1.3.2  The insulin-like growth factors system (review in ref. [6-10]) 
 
The insulin-like growth factor system ( also known as IGF axis) is a cell signaling system 
including two ligands, the insulin-like growth factor 1 and the insulin-like growth factor 2 
(IGF-1 and IGF-2), two cell surface insulin-like growth factor receptors (IGF1R and 
IGF2R), at least six different insulin-like growth factor binding proteins (IGFBP1-6) [10], 
and multiple IGFBP proteases [52].   
 
1.3.2.1   The insulin-like growth factors 
 
The insulin-like growth factors (IGFs) are polypeptides with high sequence similarity to 
insulin. IGFs are part of a complex system that is involved in the regulation of a diverse 
array of biological functions, both normal and pathological in vertebrate species. There are 
two main IGFs, IGF-1 and IGF-2, that have been isolated and characterized [53].  IGF-1 and 
IGF-2 are 70% identical to one another, and 50% to pro-insulin. Both IGFs have 
characteristics of a circulating hormone and a tissue growth factor.  
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IGF-1 is a single chain polypeptide of 70 amino acids, with a molecular weight of 7,649 D 
[53].  The gene encoding IGF-1 is located on chromosome 12q22-q23 [54]. IGF-1 is            
a growth factor that circulates at high levels in the blood stream. The majority of circulating 
IGF-1 is produced in the liver. However, many other tissues including bone, adipose tissue, 
kidney, and muscle also produce IGF-1 and are sensitive to its action, especially during 
postnatal development [9].  The regulation of IGF-1 production in hepatic tissue is mainly 
mediated by growth hormones and insulin. In turn, IGF-1 feeds back to suppress growth 
hormones and insulin release. In addition to growth hormones, developmental factors as 
well as the nutrition status can modify IGF-1 production [9,55].  The action of IGF-1 is 
mediated by binding to specific receptors present on most cell types. IGF-1 is one of the 
most potent natural stimulators of cell growth (increase in the size of the cells), cell 
proliferation (increase in the number of cells) and a potent inhibitor of programmed cell 
death.  In mammals, IGF-1 is required for both pre- and postnatal growth, however 
relatively low expression during the embryonic period indicates that it is more important for 
post-natal growth and development [56,57].   
 
IGF-2, like IGF-1, is a single polypeptide, with a molecular weight of about 7.4 kD [58]. 
The gene for IGF-2 is located on chromosome 11p15.5 [54].   The synthesis of IGF-2 is 
relatively independent of growth hormones. Its expression is much higher during fetal 
development than during post-natal life.  IGF-2 plays a fundamental role in embryonic and 
fetal development, whereas its role in post-natal period is less important since it is 
substituted by IGF-1 [59].  
 
Most circulating IGF-1 and IGF-2 molecules form a complex to a family of IGF binding 
proteins (IGFBPs). IGF binding protein 3 (IGFBP3) is the predominant IGFBP in serum and 
almost 70% of the bound IGF is carried as a trimeric complex with IGFBP3 and the acid-
labile subunit (ALS) which modulates the availability of free IGFs [8,10]. IGFBPs 
coordinate and regulate the biological activities of IGFs by acting as transport proteins in 
plasma, controlling the efflux of IGFs from the vascular space, and regulating IGFs 
metabolic clearance. Furthermore, IGFBPs can directly modulate the interaction of IGFs 
with their receptors and thereby indirectly control their biological actions [10].    
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1.3.2.2  The biological actions of IGFs 
 
In general, the effects of IGFs in vitro are either acute anabolic effects on protein and 
carbohydrate metabolism, or long term effects on cell proliferation and differentiation [10].   
The most widely studied effect of IGFs on cell cycle progression in vitro is the stimulation 
of DNA synthesis and cell proliferation, by causing cells to traverse the successive phases of 
the cell cycle. IGF-1 had been shown to function as an inducing factor for cell cycle 
progression, and this function has been studied extensively in BALB/c-3T3 cells [60-62].  
The critical function of IGF-1 for the stimulation of cell proliferation is demonstrated 
intensively in a variety of cell types. IGF-1 has been shown being a potent mitogenic factor 
stimulating cell proliferation in fibroblasts, chondrocytes, smooth muscle cells, and 
epithelial cells, e.g. [10].    
 
 In vivo, the absolute requirement of IGFs for normal development is demonstrated by the 
severe growth retardation and developmental defects in various organs, and sterility in   
IGF-1 knock-out mice [56]. In humans, deletions in the IGF-1 gene result in severe pre- and 
postnatal growth and developmental defects and in mental retardation [11]. Moreover, 
several model systems have provided evidence that proliferation and metastasis of cancer 
cells are increased by IGFs receptor activation, either in relation to higher levels of 
circulating IGFs [63] or overexpression of the IGF receptors [64].  IGFs also control tissue 
homeostasis throughout life by providing essential signals for the regulation of cell growth, 
cell proliferation, cell cycle progression, cell differentiation, and cell survival [10].  
 
1.3.2.3  The insulin-like growth factor receptors  
 
The biological effects of IGF-1 and IGF-2 are mediated by their cell surface receptors. IGFs 
bind to three receptors with differing affinities. The type 1 IGF receptor binds both IGF-1 
and IGF-2 with high affinity. Virtually all of the biological activities of the IGFs result from 
binding to the type 1 IGF receptor. The type 2 IGF receptor binds IGF-2 with high affinity 
and IGF-1 with low affinity. This receptor does not transduce a signal because it lacks          
a tyrosine kinase domain but acts as a negative regulator of IGF activity by sequestration, 
endocytosis and degradation of IGF-2 [65]. The insulin receptor binds IGF-1 with an affinity 
approximately 100-fold lower than insulin [10].  
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The IGF-1 receptor (IGF1R) is a hetero-tetrameric receptor tyrosine kinase which carries out 
most of the biological activities of IGFs [66]. The gene encoding IGF1R is a single copy 
gene located on chromosome 15q26 and encodes a single polypeptide of 1,367 amino acids 
[54]. The IGF1R is synthesized as a single-chain pre-proreceptor which is subsequently 
terminally glycosylated and proteolytically cleaved to yield the α-subunit (130-135 kD) and 
β-subunit ( 90-97 kD) of the mature receptor [67]. These assemble into a disulphide-linked 
hetero-tetramer comprised of two extracellular α-subunits containing the extracellular 
cysteine-rich domain necessary for ligand recognition and binding, and two transmembrane 
β-subunits transmitting the ligand-induced signal. The IGF1R β-subunit consists of three 
domains: a juxtamembrane domain with motifs required for recruiting the major signaling 
adapter proteins; a tyrosine kinase domain which is essential for the catalytic activity of the 
receptor; and the carboxy-terminal domain which has several important residues for IGFR 
signaling [67,68] (see Fig. 3).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Scheme of the structural model fo the IGF1R. The disulphide (-ss-)- linked hetero-
tetramer of the IGF1R molecule comprises of two α–subunits (light blue) and two β–subunits 
(light violet). Intracellular activities of the IGF1R signaling cascade are initiated via the 
interaction between the IGF-1 molecule (blue) with the ligand binding site of the α–subunits of 
IGF1R. 
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The IGF1R gene is constitutively expressed in most tissues and cell types, consistent with the 
role of IGF-1 as a progression factor through the cell cycle. Usually, high levels of 
expression are seen at embryonic stages which are characterized by a large proportion of 
actively proliferating cells. The level of IGF1R mRNA decreases in post-natal proliferating 
cells and reaches the lowest level in post-mitotic fully differentiated adult cells [10]. The 
importance of the IGF1R in normal mammalian development is observed in IGF1R null mice 
which are 45% of the size of wild type animals at birth, and die shortly after birth due to 
severe organ hypoplasia [69].  Mouse embryonic fibroblasts cultured from IGF1R null mice 
(R-cells) grow more slowly than wild type cells, and they are unable to proliferate under 
anchorage-independent conditions [70].  The IGF1R can induce differentiation in adipocytes, 
myoblasts, osteoblasts, neurons, and haematopoietic cells [71].  Activation of the IGF1R 
protects cells from killing induced by a variety of agents, including osmotic stress, hypoxia, 
radiation, and anti-cancer drugs [72,73].   
 
 
1.3.3  The IGFs/IGF1R signal transduction pathways   
 
Binding of IGFs to the extracellular part of IGF1R initiates the cytoplasmic signaling 
cascades that include conformational change of the receptor which enables IGF1R to bind 
ATP and become autophosphorylated at tyrosine residues within the β-subunits.               
This result in activation of the intrinsic tyrosine kinase activity of the IGF1R and 
subsequently tyrosine phosphorylation of several substrates which lead to the activation of 
intracellular signaling pathways, allowing induction of growth, proliferation, transformation, 
differentiation, and survival (see Fig. 4).     
 
The proximal substrates for IGF1R include the insulin receptor substrate 1-4 (IRS1-4)    [74-
77] and the Src-homology collagen protein (Shc) [78]. Once activated, Shc and IRSs bind to 
a complex of the growth factor receptor bound-2 (Grb2) and Son of sevenless (Sos). This 
complex allows the activition of Ras and its downstream cascade, the Ras/Raf/mitogen 
activated protein kinase and extra-cellular-signal-regulated kinase kinase (MEK)/extra-
cellular-signal-regulated kinase (ERK) pathway. The Ras/Raf/MEK/ERK cascade is involved 
in cell proliferation, differentiation, and protection against apoptosis.  
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Activated IRS proteins also bind to the p85 regulatory subunit of the phosphatidylinositol   
3-kinase (PI3K). The activation of PI3K leads to an increase in the phosphatidyl inositol 
3,4,5 triphosphate (PIP3) level that induces the recruitment of Akt (protein kinase B). This 
allows the constitutively activated 3’-phosphoinositide-dependent kinases (PDK)-1 and   
PDK-2 to phosphorylate and activate Akt. Many downstream targets of Akt have been 
shown to prevent apoptosis and to stimulate cellular proliferation or glucose transport        
[6-10,79]. The mammalian Forkhead members of the class O (FOXO) transcription factors 
are well-characterized substrates of Akt.  Phosphorylation of FOXOs by Akt results in the 
retention of FOXOs in the cytoplasm [80]. In the absence of PI3K/Akt signaling, FOXOs 
translocate to the nucleus and activate transcription of their target genes, including those that 
encode proteins that induce cell cycle arrest (e.g., p130 and p27) and apoptosis (e.g., Fas 
ligand, Trail, and Bim) [81].    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             modified from Dupont, 2003 [82] 
 
Figure 4. Scheme of the IGF1R activation and downstream signalings. Following ligand 
(IGFs) binding to IGF1R, tyrosine kinase activity of IGF1R is activated, and this stimulates 
signaling through intracellular networks that regulate cell proliferation and cell survival. Key 
downstream networks include the Ras/Raf/MEK/ERK and the PI3K/Akt pathways. Two other 
mitogen-activated protein (MAP) kinases, p38 and JNK, are also activated in response to 
IGF-1. The MAP kinases are involved in cell survival, differentiation, proliferation, and 
protection against apoptosis. The PI3K/Akt pathway is involved in protein translation, cell 
survival, proliferation, apoptosis, and glucose metabolism (see more details in the text). 
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1.3.3.1  The Ras/Raf/MEK/ERK signaling ( review in ref. [83-86] ) 
 
One of the most important pathways activated by IGFs is the Ras/Raf/MEK/ERK cascade 
[7]. The Ras/Raf/MEK/ERK cascade is a signal transduction pathway that transmits signals 
from extra-cellular stimuli to regulate cellular processes such as proliferation, 
differentiation, cell cycle progression, and prevention of apoptosis [85].  
 
Following binding of ligands to their specific cell surface receptors, activation of the 
coupling complexes Shc/Grb2/Sos or IRSs/Grb2/Sos occur and induce the activation of Ras, 
a small GTP-binding protein. The inactive GDP-bound conformation of Ras exchanges into 
the active GTP-bound conformation [84]. The GTP-bound active Ras can then recruit Raf,   
a serine/threonine kinase, to the cell membrane for subsequent activation by phosphorylation 
[87].  
 
Raf is normally activated by a complex series of events including: recruitment to the plasma 
membrane mediated by an interaction with Ras [88], dimerization of Raf proteins [89], 
phosphorylation/dephosphorylation at different domains [90], dissociation from the Raf 
kinase inhibitory protein (RKIP) [91], and association with scaffold complexes [92].  Raf 
activity is further modulated by chaperone proteins including 14-3-3 [93] and heat shock 
protein 90 (Hsp90) [94].  
 
Activated c-Raf phosphorylates and activates MEK1/2 [95], which in turn activate the 
effector proteins ERK1 and ERK2 by phosphorylation of the Thr and Tyr residues within 
their activation loop [96]. ERK1/2 as well as their direct target substrate, p90 ribosomal     
s6 kinase (p90RSK), enter into the nucleus upon activation, where they phosphorylate and 
activate transcription factors including c-myc, AP-1, TCF/Elk-1, c-Ets-1, and c-Ets-2 
leading to the expression of the immediate early gene FOS and others [97-99] (see Fig. 5).  
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Figure 5. Scheme of the Ras/Raf/MEK/ERK cascade. Growth factor stimulation of the 
Ras/Raf/MEK/ERK pathway leads to sequential activation of Ras and Raf, which in turn 
activates MEK1 and MEK2. MEK1/2 are dual-specificity kinase that are essential to the 
propagation of growth factor signaling and are known to amplify signals to ERK1/2 that in turn 
can phosphorylate and activate a range of proteins including several transcription factors 
leading to the expression of FOS and others (see more details in the text). 
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1.3.3.2  c-Fos, a  downstream target of the Ras/Raf/MEK/ERK cascade 
 
c-Fos is a member of the Fos family of transcription factors including c-Fos, FosB, Fra-1, 
and Fra-2. c-Fos is the product of FOS, a proto-oncogene belonging to the immediate early 
genes (IEGs) that are rapidly activated in response to various cellular stimuli  [100,101].  
The proper regulation of FOS expression is important in many cellular processes including 
proliferation, differentiation, and oncogenic transformation [102].  FOS is located on the 
long arm of  chromosome 14 (14q21-31); it contains four exons, spans approximately 4 kb, 
and encodes a 380 amino acid protein of 55 to 62 kD [103,104].   
 
c-Fos has a bZIP region consisting of a basic DNA-binding domain, a leucine zipper 
domain, and a transactivation domain at the C-terminus [105]. The promoter of FOS is 
organized into the serum response element (SRE), the c-Sis inducible element (SIE), the 
TCF (ternary complex factor), the calcium response element (CRE), and the AP-1/CRE 
[101,106].  The SRE is involved in the induction of c-Fos in response to growth factors, 
phorbol esters, and ionizing radiation [101]. Serum and growth factors potently induce FOS 
expression by activating ERK. Activated ERK translocates to the nucleus to phosphorylate 
TCFs thereby provoke the transcriptional activity of TCFs that bind to FOS promoters.  
 
Fos proteins together with Jun family members, c-Jun, JunB, and Jun D, can form  the 
complexes that bind to AP-1 ( activating protein-1) regulatory elements in the promoters and 
enhancer regions of numerous mammalian genes [107]. The AP-1 binding site occurs with   
a high frequency in the genome, and it is likely that Fos-Jun family proteins regulate all 
genes that contain AP-1 recognition sequences [108]. 
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1.3.3.3  Cyclin D1, the target of the IGF-1 signaling cascade  
 
Cyclin D1, a 295 amino acids protein with a molecular weight of about 34 kD, is the product 
of the CCND1 (also known as PRAD1) gene located on the long arm of  chromosome 11 
(11q13) [109-112]. This gene spans about 15 kb and has five exons.  Induction of CCND1 is 
induced by growth factors including IGF-1, IGF-2, and epithelial growth factor, and 
hormones including androgen, retinoic acid, and peroxisome proliferator-activated receptor 
γ ligand [113]. Growth factor stimulation typically activates CCND1 mRNA production 
through coordinated activation of several families of transcription factors, including 
activator protein-1 (AP-1) [114-116], nuclear factor-κB (NF-κB) [117], Sp1 [118], cyclic 
AMP response element-binding protein (CREB) [118], ternary complex factor (TCF) [119]. 
Once produced, the CCND1 transcript is processed by post-transcriptional mechanisms 
including mRNA stability, sub-cellular localization, and targeted protein degradation     
[120-122] (see Fig. 6). Following mitogen stimulation, the cyclin D1 protein appears rapidly 
in early G1 phase before cyclin E and declines rapidly when the growth factors are 
withdrawn [123].  
 
IGF-1 is one of the best-known growth factors that activate the CCND1 expression. 
Activation of Ras/Raf/MEK/ERK, the major pathway downstream of IGF-1 signaling, 
induces transcription of the CCND1 gene [124,125]. The PI3K/Akt and/or mTOR, other 
major pathways downstream of IGF-1, also activate the CCND1 transcription and mRNA 
translation [125]. Moreover, activation of PI3K/Akt also induces a stabilization of cyclin D1 
protein by inactivating glycogen synthase kinase 3 beta (GSK-3β) [125]. Abundance of 
cyclin D1 is regulated by its cellular localization and protein degradation [126]. During G1 
phase, cyclin D1 localizes to the nucleus and re-localizes to the cytoplasm during S phase 
[123]. The phosphorylation of cyclin D1 at threonine 286 residue by GSK-3β in the nucleus 
results in the relocalization of cyclin D1 to the cytoplasm during S phase where it is 
degraded by the proteaosome [127-129].  The level of cyclin D1 increases again during G2 
phase and sustains through M and G1 phases [130].     
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Figure 6. Scheme of the regulation of the CCND1 gene and cyclin D1 protein by the IGF-1 
signaling cascade. The major pathways downstream of the IGF-1 signaling cascade which 
regulate CCND1 transcription, translation, and cyclin D1 protein stabilization are illustrated 
(see more details in the text). 
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1.3.4 The regulation of cell cycle progression through G1 phase  
 
1.3.4.1 The cell cycle  
 
The cell cycle is ubiquitous, complex process for the growth and proliferation of the cells 
and organismal development [131,132].  The cell cycle can be subdivided into interphase 
and mitosis phase (M). There are three stages in interphase, Gap1 phase (G1), Synthesis 
phase (S), and Gap2 phase (G2). Mitosis phase is divided into the four stages prophase, 
metaphase, anaphase, and telophase [131,133]. During mitosis, the chromosomes are 
separated and the cell divides into two daughter cells. After division, the cells are back in G1 
phase and the cell cycle is completed. The duration of the cell cycle varies between different 
cell types. In most mammalian cells, it lasts between 10 and 30 hours. Cells in G1 phase do 
not always continue through the cycle. Instead, they can exit from the cell cycle and enter a 
resting stage (G0) [134,135]. 
 
 
1.3.4.2   The regulation of the cell cycle ( review in ref. [123,132,136-138] ) 
 
For all living eukaryotic organisms it is essential that the different phases of the cell cycle 
are precisely coordinated. The phases must follow in correct order, and one phase must be 
completed before the next phase can begin. The cell cycle is regulated in eukaryotic cells by 
the periodic activation of different cell cycle phase-specific proteins known as cyclin-
dependent kinases (Cdks) and cyclins. Cdks are serine/threonine protein kinases that are 
activated at specific points in the cell cycle. The Cdks are important for the cell cycle 
because their inactivation state prevents mitosis.  Cdks are regulated by several factors such 
as phosphorylation at threonine and tyrosine residues and binding to cyclins. Cyclins target 
Cdks to the nucleus where they can phosphorylate a variety of substrates, thereby catalyzing 
the process of cell division.   
 
The expression levels of cyclins during cell division are periodic (see Fig. 7). In general, 
before a cell can enter a new phase of cell cycle, the cyclin of the previous phase is 
degraded, and the cyclin of the next phase is synthesized. Following mitogen stimulation of 
quiescent cells, genes encoding D-type cyclins are activated at the beginning of G1 phase 
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and followed by expression of E-type cyclins promoting G1/S phase transition [120,139]. 
Cyclin A accumulates during S phase and peaks at G2 [140]. Its activation pushes the 
progression of the cell through S and G2 phases. The synthesis of Cyclin B is initially 
induced and accumulates at late S phase but peaks at G2/M phase triggering the G2/M 
transition [141]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Scheme of the periodic expressions of cyclins and cyclin-Cdk complexes during 
cell cycle progression. The different stages of the cell cycle are quiescence (G0), G1 phase, the 
DNA synthesis phase (S), G2 phase, and mitosis phase (M).The major mammalian cyclin-Cdk 
complexes active in specific phases of cell cycle are illustrated. A blue broken line represents 
the declination of cyclin D level when the cell terminates from the cell cycle or when growth 
factors are withdrawn (see more details in the text).   
 
1.3.4.3 The regulation of G1 to S phase transition    
 
Progression through G1 phase in mammalian cells requires growth factor induced signal 
transduction [142]. Growth factors exert most of their action on cells at the G1/S restriction 
point [143]. After the restriction point in G1 is passed, the cell cycle progresses largely 
independently of growth factors [144]. The transition that occurs at the restriction point in 
G1 commits the cells to the proliferative cycle. Passage through the restriction point and 
transition to S phase is initiated by D-type cyclins (D1, D2, D3), the first cyclins produced in 
the cell cycle [145-147]. Following its expression, cyclin D initiates cell cycle progression 
towards S phase by its binding to either cyclin dependent kinase 4 (CDK4) or cyclin 
dependent kinase 6 (CDK6), dependent on cell type, and activates the kinase moiety [148].  
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Once activated,  the cyclin D-CDK4/6 complex promotes cell cycle progresstion by 
inactivating the retinoblastoma tumor suppressor protein (Rb) [149-151]. In its 
hypophosphorylated state, Rb silences specific genes through its ability to form 
transcriptional repressor complexes with E2F transcription factors on the promoters of genes 
that are active in the S phase of the cell cycle [152]. The cyclin D-CDK4/6 complex 
mediates phosphorylation of Rb (pRb). pRb dissociates from E2F, thus releasing its 
transcriptional repressor function.  In the absence of Rb, E2F (along with its binding partner 
DP-1) mediates the trans-activation of E2F target genes including CCNE (encodes cyclin E), 
CCNA (encodes cyclin A), POL (encodes DNA polymerase), TK (encodes thymidine 
kinase), etc. genes that facilitate the G1/S transition and S phase progression [152,153].  
 
One of the most important targets activated by cyclin D1 is the CCNE gene. Cyclin D1 
induces the expression of CCNE by two distinct mechanisms, either through E2F activation 
or through the sequestration of the Cip/Kip cell cycle inhibitors such as p21 or p27  [154]. 
Cyclin E binds to CDK2, forming the cyclin E-CDK2 complex, which pushes the cell from 
G1 to S phase (see Fig. 8).  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 8. Scheme of the regulation of G1 to S phase transition by cyclin D1. At the beginning of 
G1 phase, growth factors or mitogens induce the expression of genes encoding D-type cyclins. The 
induced cyclin D associates to Cdk4/6 which phosphorylate and inactivate the retinoblastoma protein 
(Rb). The inactivated Rb fails to suppress the E2F transcription factor which controls the expression 
of genes required for the G1/S transition and S phase progression including the cyclin E gene. 
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2.  MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 List of antibodies used in this study  
 
2.1.1.1 Antibodies for immunofluorescence staining and PI3K activity assay 
 
antibody, catalog number, source,                 
working dilution [antibody (μl):blocking buffer (μl)] 
Supplier 
Alexa Fluor 488, A11029, goat anti-rabbit IgG, 
1:200 
Invitrogen, Karslruhe, Germany 
Cy3TM, 200-162-037, goat anti-mouse IgG, 1:500 
Jackson ImmunoResearch Lab, 
Inc., West Grove, USA 
Erk1/2, 9102, rabbit, 1:100 
Cell Signaling Technology/ New 
England Biolab, Frankfurt a. Main, 
Germany 
Nbs1, 1D7, mouse, 1:250 BioMol, Hamburg, Germany 
p85 subunit of PI3 kinase, 06-197, rabbit              
(2 μl/1.5 mg of protein) 
Upstate/Millipore GmbH, 
Schwalbach, Germany 
phosphotyrosine , 05-777, mouse,                         
(2 μl/1.5 mg of protein) 
Upstate/Millipore GmbH, 
Schwalbach, Germany 
 
2.1.1.2 Antibodies for Western blot 
 
antibody, catalog number, source,                 
working dilution [antibody (μl):blocking buffer (ml)] 
Supplier 
β-Actin, I-19 sc-1616, goat, 1: 4 
Santa Cruz Biotechnology Inc., 
USA  
Akt1, 2967, rabbit, 1:1 
Cell Signaling Technology/ New 
England Biolab, Frankfurt a. Main, 
Germany 
Materials amd Methods 
 23
antibody, catalog number, source,                 
working dilution [antibody (μl):blocking buffer (ml)] 
Supplier 
phospho-S473-Akt, 9271, rabbit, 1:1 
Cell Signaling Technology/ New 
England Biolab, Frankfurt a. Main, 
Germany 
Cyclin A, 611268, mouse, 1:2 BD Biosciences, Germany 
Cyclin D1, CC12, mouse, 7:1 
Calbiochem-Novabiochem, Bad 
Soden, Germany 
Cyclin E, ab3927, mouse, 1:2 Genetex, Abcam, Germany 
Erk1/2, 9102, rabbit, 1:1 
Cell Signaling Technology/ New 
England Biolab, Frankfurt a. Main, 
Germany 
phospho-Thr202/Tyr204-Erk1/2, 9101, rabbit, 1:1 
Cell SignalingTechnology, 
Frankfurt a. Main, Germany 
c-Fos, sc-52, rabbit, 1:1 
Santa Cruz Biotechnology Inc., 
USA 
FOXO1, sc-11350, rabbit, 1:1 
Santa Cruz Biotechnology Inc., 
USA 
Mre11, ab3621-50, rabbit, 1:1 Genetex, Abcam, Germany 
Nbs1, 1D7, Mouse, 1:1 BioMol, Hamburg, Germany 
Phospho-Nbs1 (Ser343), 05-663, mouse, 2:1 
Upstate/Millipore GmbH, 
Schwalbach, Germany 
Rad50, GT70228, Mouse, 1:2 Genetex, Abcam, Germany 
phospho-s338-c-Raf, 56A6-9427, rabbit, 1:1 
Cell Signaling Technology/ New 
England Biolab, Frankfurt a. Main, 
Germany 
Sos1, sc-256, rabbit, 2:1 
Santa Cruz Biotechnology Inc., 
USA 
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antibody, catalog number, source,                 
working dilution [antibody (μl):blocking buffer (ml)] 
Supplier 
Sos2, sc-258, rabbit, 2:1 
Santa Cruz Biotechnology Inc., 
USA 
Donkey anti-goat IgG-HRP, sc-2033, 0.3:20 
Santa Cruz Biotechnology Inc., 
USA 
Goat anti-mouse IgG-HRP, sc-2005, 0.3:20 
Santa Cruz Biotechnology Inc., 
USA 
Goat anti-rabbit IgG-HRP, sc-2004, 0.3:20 
Santa Cruz Biotechnology Inc., 
USA 
IGF-1Rα, N-20 sc-712, rabbit, 5:1 
Santa Cruz Biotechnology Inc., 
USA 
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2.1.2 List of buffers, medium, and solutions used in this study  
 
2.1.2.1 Buffers and solutions for immunofluorescence staining.  
 
1% Bovine Serum Alblumin (BSA) 
Dissolve 1 g BSA in 100 ml PBS and stir until it dissolves.  
 
4% Paraformaldehyde (PFA) 
Dissolve 4 g PFA on day of use in 100 ml PBS by heating at 60°C and 
stirring until it dissolves. Cool before use.     
 
0.2% Triton X-100 
Prepare stock of 20% Triton X-100 in PBS; rotate tube overnight to dissolve.  
Dilute to 0.2% with PBS 
 
2.1.2.2 Buffers and solutions for PI3K activity assay. 
 
Lysis buffer 
  20 mM Tris/HCl, pH 7.5 
137 mM NaCl 
1 mM CaCl2 
1 mM MgCl2 
0.1 mM Na3VO4 (add before use) 
0.3% Triton X-100 
 
Reaction buffer 
20 mM Tris/HCl, pH 7.5 
100 mM NaCl 
0.5 mM EGTA 
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2.1.2.3 Buffers and solutions for Western blot analysis  
 
Blocking buffer for antibody detection   
5% non fat dry milk powder in TBS-T solution 
 
Laemmli gel loading buffer (4X) 
100 mM Tris-HCl pH 6.8 
4% SDS 
0.2% Bromophenol blue 
20% Glycerol 
200 mM DTT  
 
5 x Laemmli Running buffer 
15.1 g Tris-Base (25 mM) 
94 g Glycine (250 mM) 
50 ml 10% SDS  
Adjust the volume to 1 l with water.  
 
NOV stock solution (100 mM) 
18.3 mg/ml water 
 
PMSF stock solution (100 mM) 
17.4 mg PMSF/ml isopropanol 
 
RIPA-Buffer–Cell lysis buffer 
150 mM NaCl 
10 mM Tris-HCl, pH 7.2 
0.1% SDS 
1% Triton X-100 
1% Deoxycholate 
5 mM EDTA 
Before using add 1:100 of 100 mM PMSF and 100 mM of NOV 
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PBS (Phosphate buffered saline) 
9.6 g PBS dissolved in 1 l water and sterilized by autoclaving 
 
SDS-PAGE (separating gel, 10%) 
375 mM Tris-HCl, pH 8.8 
10% Acrylamid/Bisacrylamid (37.5/1) (ProtogelTM ) 
0.1% SDS  
0.1% APS 
0.01% TEMED 
 
SDS-PAGE (stacking gel, 5%) 
125 mM Tris-solution pH 6.8 
5%  Acrylamid / Bisacrylamid (37.5/1) (ProtogelTM ) 
0.1% SDS  
0.1% APS 
0.01% TEMED 
 
Stripping Puffer 
2% SDS (20 g/l) 
62.5 mM TrisHCl (9.9 g/l) 
100 mM ß-Mercaptoethanol (7 ml/l) 
 
10 x TBS-T (pH 7.6) 
20 mM Tris-Base (2.4 g/l) 
137 mM NaCl (8 g/l) 
0.1% Tween 20 (1 ml/l) 
 
Towbin Puffer (blotting buffer) 
3 g Tris-Base 
14.4 g Glycine 
  200 ml Methanol, adjust the volume to 1 liter with distilled water.  
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2.1.2.4 Medium for cell culture 
 
For RPE cell lines    
DMEM-F12 (1:1) (PAA) 
10% FCS (PAA) 
17.3 ml of  7.5% sodiumbicarbonate 
40 U/ml penicillin, 40 µg/ml streptomycin 
 
2.1.2.5 Solutions for cell cycle analysis 
 
Solution I (prepare 500 ml stock) 
  NaCl     584  mg/l 
  Na-citrate    1,000  mg/l 
  RNase A from bovine pancreas 10  mg/l   
  Nonidet P-40    0.3 mg/l 
 
Solution II (prepare 500 ml stock) 
  Citric acid    15 g/l 
  Sucrose    0.25 mM 
Add 50 ug/ml propiodium iodide to each solution before use.  
 
2.1.2.6 Solutions for cell treatment 
 
Aphidicholin  
Dissolve aphidicholin in DMSO to a concentration of 2 mg/ml.  
Aliquot and store at -20°C.   
 
IGF-1 stock solution 
Dissolve lyophilized IGF-1 in sterile water to a concentration of 0.1 mg/ml. 
Aliquot and store at -20°C.   
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U0126 stock solution 
 Dissolve U0126 in DMSO to a concentration of 10 nM. Aliquot and store at -
20°C.   
  
Wortmannin stock solution 
 Dissolve wortmannin in DMSO to a concentration of 50 mM and store at    
4°C.   
 
 
2.1.3 List of chemicals and materials used in this study 
 
Chemical or material Supplier 
Absolute Ethanol Merck KG aA, Darmstadt, Germany 
Agarose gel  Biozym, Hess. Oldendorf, Germany 
Ampicillin Serva, Heidelberg, Germany 
APS Merck KG aA, Darmstadt, Germany 
Aphidicolin 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
[γ-32P]ATP 
Hartmann-Analytik, Braunschweig, 
Germany 
Blotting Grade Blocker Non-Fat Dry Milk Biorad, Munich, Germany 
Boric acid Merck KG aA, Darmstadt, Germany 
Bradford reagent 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
Bromophenol blue Molecular Diagnostics, Mannheim 
BSA 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
Citric acid Merck KG aA, Darmstadt, Germany 
Chloroform Merck KG aA, Darmstadt, Germany 
Colorimetric cell proliferation kit I (MTT)   
Roche Molecular Biochemicals, 
Mannheim, Germany 
Deoxycholate Merck KG aA, Darmstadt 
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Chemical or material Supplier 
DEPC 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
DMEM 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
DMSO 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
DTT Serva, Heidelberg, Germany 
EDTA 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
Ethidium bromide Serva, Heidelberg, Germany 
FCS PAA Laboratories, Austria 
LightCycler Faststart Reaction Mix SYBR 
Green I 
Roche Molecular Biochemicals, 
Mannheim, Germany 
Magnesium chloride Merck KG aA, Darmstadt, Germany 
2-Mercaptoethanol Merck KG aA, Darmstadt, Germany 
Methanol Merck KG aA, Darmstadt, Germany 
Neomycin 
Calbiochem-Novabiochem, Bad 
Soden, Germany 
Nonidet P-40 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
Nuclear and cytoplasmic extraction kit (NE-
PER) 
Perbio Science Deutschland GmbH 
Bonn, Germany 
Paraformaldehyd 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
Penicillin/Streptomycin Gibco BRL, Karlsruhe, Germany 
Phosphate Buffered Saline 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
PMSF 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
Polyfect Transfection Reagent QIAGEN GmbH, Hilden, Germany 
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Chemical and material Supplier 
Ponceau S 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
Propidiumiodide  Sigma, USA 
ProtogelTM Natioal Diagnostics., Atlanta, USA 
Roti-buffer Roth GmbH, Karlsruhe, Germany 
SDS Serva, Heidelberg, Germany 
SiLentFect Lipid Biorad, Munich, Germany 
siRNA (NBS1 and scramble ) Ambion (Europe) Ltd, U.K. 
siRNA (NBS1 stealth and scramble stealth) Invitrogen, Karlsruhe, Germany 
Sodium citrate  Merck KG aA, Darmstadt, Germany 
Sodium bicarbonate Merck KG aA, Darmstadt, Germany 
Sodium chloride Merck KG aA, Darmstadt, Germany 
Sodiumorthovanadate 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
Sucrose Merck KG aA, Darmstadt, Germany 
SuperScript Reverse Transkriptase Invitrogen, Karlsruhe, Germany 
TEMED 
Pharmacia Biotech GmbH, Freiburg, 
Germany 
Tris  Merck KG aA, Darmstadt, Germany 
Triton X-100  Merck KG aA, Darmstadt 
Trypsin GibcoBRL, Karlsruhe, Germany 
TRIzol  Invitrogen, Karslruhe, Germany 
Tween-20  Merck KG aA, Darmstadt, Germany 
U0126 
Cell Signaling Technology/ New 
England Biolab, Frankfurt a. Main, 
Germany 
Vectashield-mounting medium 
Vector Laboratories, Burlinggame, 
USA 
Wortmannin 
SIGMA-Aldrich Chemie GmbH, 
Deisenhofen, Germany 
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2.1.4 List of instruments used in this study 
 
Instrument Supplier 
Agarose gel electrophoresis-Apparatus 
(Wide-Mini-) Sub Cell GT, Biorad, 
Munich, Germany 
Blotting-Apparatus 
Trans-Blot SD Semi-Dry Transfer 
Cell, Biorad, Munich, Germany 
Blotting-paper 
WhATMann 3 mm, Schleicher & 
Schuell GmbH, Dassel, Germany 
Cell culture flask  
• Greiner Labotechnik Bio-One 
GmbH, Frickenhausen, Germany 
Cell culture dish • Nunc, Dänemark, Germany  
Centrifuge 
• Eppendorf centrifuge 5415c, 
Eppendorf, Hamburg, Germany 
• Multifuge 3SR, Heraeus, Hanau, 
Germany 
• Sigma 2K15 and Sigma 3K15, 
Sigma 
Laborzentrifugen GmbH, Osterode 
am Harz, Germany 
CO2 - Incubator Sanyo, Japan 
Cryo tube Kisker-Biotech, Mühlhausen, 
Germany 
Fluorescence-activated cell sorting and 
software 
BD LSRII (Scanner), FACS-Scan, 
FACStar Plus (Sorter), BD 
FACSDiva software, Becton 
Dickinson, USA 
Glass ware 
• Braun, Melsungen, Germany 
• Schott, Mainz, Germany 
Incubator 
• Heraeus, Hanau, Germany 
• Memmert, Schwabach, germany 
• Sanyo, Japan 
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Instrument Supplier 
Laminar flow clean bench 
Larminar Flow, BDK, Sonnenbühl-
Genkingen, Germany 
Light Cycler 
Roche Molecular  Diagnostics, 
Mannheim, Germany 
Magnetic stirrer 
Ikamag RCT, IKA-Labortechnick, 
Staufen i.Br., Germany 
Microscope 
• Axiovert 25CF, Zeiss, Jena, 
Germany 
• LSM 510, Zeiss, Jena, Germany  
• Olympus LH50A, Olympus Optical 
Co., Hamburg, Germany 
Nitrocellulose Membrane Protran 0,2 mm, Schleicher &Schuell 
PAGE-Apparatus 
Hoefer Mighty SmallTM SE245, 
Dual Gel Caster, Amersham 
Pharmacia Biotech, Freiburg, 
Germany 
Pipette Eppendorf, Hamburg, Germany 
pH-Meter  InoLab pH Level 1, UK 
Power supply unit 
• Biorad, munich, Germany 
• Consort electrophoresis power 
supply, Fröbel Labortechnik GmbH, 
Lindau, Germany 
• Electrophoresis Power Supply-
EPS600, Amersham Pharmacia 
Biotech, Freiburg, Germany 
Film 
X-Omat AR Film, Kodak, Stuttgart, 
Germany 
Film processing machine 
Optimax Typ TR, MS Labogeräte, 
Wiesloch, Germany 
Reaction tube 
0.5 ml, 1.5 ml, 2.0 ml Eppendorf 
Hamburg, Germany 
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Instrument Supplier 
Reaction tube 
• 15 ml, 20 ml Falcon USA and 
Greiner Labotechnik Bio-One 
GmbH, Frickenhausen, Germany 
• FACS-tube, Falcon, USA 
• PCR-tube, Biozym Diagnostik, 
hess-Oldendorf, Germany 
Refrigerator  
• Liebherr GmbH, Lienz, Germany 
• Privileg, Quelle, Fürth, Germany 
• Sanyo, Japan 
Scanner Umax, powerLook 1000, Willich 
Photometer  
BioFotometer, Eppendorf, Hamburg, 
Germany 
UV-Transilluminator 
Vilber lourmat, AGS, Heidelberg, 
Germany 
Water Bath  
Frigomix U1, Braun, Melsungen, 
Germany 
 
 
2.1.5 List of oligonucleotide primers for real time PCR 
 
Target gene, catalog number Supplier 
B2M, QT00088935 QIAGEN GmbH, Hilden, Germany 
CCND1, QT00495285 QIAGEN GmbH, Hilden, Germany 
FOS, QT00007070 QIAGEN GmbH, Hilden, Germany 
NBS1 Metabion international AG, Germany 
SOS1, QT00030814 QIAGEN GmbH, Hilden, Germany 
SOS2, QT00096936) QIAGEN GmbH, Hilden, Germany 
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2.2 Methods 
 
2.2.1 Cell culture 
  
The telomerase-positive, immortalized human retinal pigment epithelial  cell line, (hTERT-
RPE) was cultured in Dulbecco’s Modified Eagle Medium (DMEM-F12) containing 2.5 
mM L-glutamine, 10% heat-inactivated fetal bovine serum, 0.25% sodium bicarbonate, 40 
units/ml penicillin G, and 40 μg/ml streptomycin. Cells were incubated at 37°C in a 
humidified atmosphere containing 5% CO2.  
 
2.2.2 Transient cell transfection with short interfering RNAs 
 
The day before transfection, approximately 8×104 cells were seeded into a 60 mm culture 
plate containing 5 ml DMEM/F12 medium and cultivated overnight such that they are 70% 
confluent in the following day. 15-60 min prior to transfection, the medium was aspirated 
from the plates and 2.5 ml fresh medium were added to each plate. For each well to be 
transfected, transfection solutions were prepared by adding 3 μl of siLentfect Lipid to 250 μl 
of serum free medium. After that, NBS1 siRNA (siNBS1; 5´-AUGAUGUGGCCAUAGAAGATT-3´, 5´- 
UCUUCUAUGGCCACAUCAUCC -3’), or scramble siRNA, or NBS1 stealth siRNA (unknown 
sequence), or scramble stealth siRNA were added to 250 μl of serum free medium as a final 
concentration of 30 nM after adding to the culture dishes. The diluted siRNAs were added to 
the diluted siLentFect Lipid and then mixed by pipetting. The mixed solutions were 
incubated for 20 min at room temperature. 500 μl of the RNA-siLentFect Lipid complexes 
were directly added to each culture dish containing 2.5 ml serum-containing medium. The 
culture plates were swirled to ensure uniform distribution of the transfection complexes and 
then incubated at cell culture condition. The transfection mixture was removed 8 h after 
transfection, and cells were washed with PBS before being incubated with fresh medium 
until the expression of target gene was fully repressed.  
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2.2.3 Cell treatments  
 
For cell treatment, the medium was aspirated from the dishes and replaced with 5 ml of fresh 
medium containing the following reagents. For aphidicolin treatment, cells were treated for 
24 h with 10 μg/ml of aphidicolin diluted in DMSO.  Subsequently, cells were released from 
blockade by washing twice with PBS before adding 5 ml fresh medium.  For IGF-1, 
U0126/IGF-1 and wortmannin/IGF-1 treatment, cells were cultured in serum-free medium 
for 48 h, pretreated with 10 μM U0126 or 100 nM wortmannin for 1 h and then stimulated 
with 100 ng/ml IGF-1.  The treated cells were collected at different time points for cell cycle 
analysis, quantitative real time PCR analysis, and Western blot analysis.  
 
2.2.4 Cell cycle analysis by flow cytometry 
 
DNA staining of isolated nuclei for cell cycle analysis was performed using a modified 
method according to Nüsse et al. (24). At each indicated time point, the treated cells were 
detached with trypsin, collected by centrifugation at 300 ×g for 5 min. The cell pellet was 
gently resuspended in 500 μl of a solution I and vortexed for a short time interval. The cell 
suspensions were incubated for 30 min at room temperature, followed by the addition of 500 
μl of a solution II. The cell suspensions were mixed and stored at 4°C before flow 
cytometric measurement. Cell cycle distributions were analyzed on a fluorescence-activated 
cell sorting (FACS) with two signal detectors, the photodiode and the photomultipier tubes, 
equipped with a laser operating at 20 mW, generating a light of 488 nm wavelength. PI 
emission was measured at wavelengths between 600 to 650 nm.   
 
2.2.5 Cell proliferation and viability assays 
 
To determine the cell proliferation rate, RPE cells were transfected with NBS1 siRNA or 
scramble siRNA. At 1 to 4 days after siRNA transfection, cells were harvested by 
trypsinization, and counted with a hemocytometer and a particle counter.  The colorimetric 
cell proliferation kit I (MTT) was used for the measurement of cell proliferation after 
stimulation with growth factor IGF-1. 24 h after transfection with siRNA, cells were seeded 
into 24-well plates and incubated for 4 h. After starvation for 24 h, cells were pre-treated 
with vehicle alone or 10 μM U0126 and subsequently stimulated with 300 µl medium 
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containing 10% FCS and 100 nM IGF-1 per well. 48 h after stimulation, 30 µl MTT labeling 
reagent was added, and cells were incubated for another 4 h. Following the addition of 300 
µl solubilization solution, the samples were incubated for an additional 12 h and absorbance 
was determined against a background control (medium only) at 595 nm. Cell proliferation 
was expressed as n-fold increase of absorbance in treated cells relative to that of untreated 
control cells. 
 
2.2.6 Colony forming assay and cell irradiation 
 
20 h after siRNA transfection, the cells were prepared into a single-cell suspension by 
trypsinization, and the cell concentration was counted. An appropriate number of cells were 
seeded into 6-well plates and then cultivated for 12 h to allow the cells to attach to the plate. 
The number of cells per plate initially seeded varies with the dose, so that the number of 
colonies surviving is in a range that can be counted conveniently. The cells pre-treated with 
or without 100 nM IGF-1 were irradiated using a Cesium-137 source with a single dose of 0, 
3, 6, or 9 Gy at a dose rate of 1.76 Gy/min at room temperature. After that, the medium was 
replaced by fresh medium and the cells were allowed to grow for 7-10 days until the 
surviving cells produced macroscopic visible colonies that can be counted easily. The cells 
were fixed with 100% ethanol for 10 min and then stained with crystal-violet for 10 min. 
Colonies containing more than 50 cells were counted and survival fractions were calculated 
from the ratio of colonies produced to the cells plated, with a correction necessary for 
plating efficiency (PE) (see equation below). 
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        Plating efficiency (PE) is the percentage of cells seeded that grow 
        into colonies without irradiation. 
 
     
 
 
 
Survival fraction (SF) is the fraction of cells surviving at a giving  
dose of radiation. 
 
 
2.2.7 PI3K activity assay 
 
PI3K activity was determined as described with slight modifications [155]. RPE cells were 
transfected with scramble siRNA or NBS1 siRNA. 48 h after transfection, cells were treated 
with or without 100 nM IGF-1 for 10 min. After that the medium was removed and cell 
extracts were prepared from approximately 60x106 exponentially growing cells.  Cell 
extracts were prepared by adding lysis buffer directly to the cells. Immunoprecipitation was 
performed by using antibodies against p85α (as a positive control) or against P-Tyr with an 
equal amount of total protein (1.5 mg). Immunocomplexes were immobilized on protein-G 
coated agarose beads and washed twice in lysis buffer, once in lysis buffer containing 0.5 M 
LiCl and twice in reaction buffer. Subsequently, the beads were resuspended in 50 µl of 
reaction buffer and 5 µg phosphatidylinositol was added from a sonified stock solution. 
Then, 5 µl of a solution of 200 mM MgCl2 and 200 µM ATP containing 20 µCi of [γ-32P] 
ATP were added to the reaction mixture. The tubes were incubated at room temperature for 
45 min before the reaction was stopped by adding 150 µl of stop solution (CHCl3/ CH3OH/ 
HCl conc., 100:200:2) and 120 µl of CHCl3. The organic phase was separated by 
centrifugation and washed once with CH3OH/HCl, 1N (1:1). The samples were 
concentrated by over night drying. The dried reaction product was re-dissolved in 10 µl 
Number of colonies counted 
 
Number of cells seeded 
× 100% Plating efficiency (PE)  = 
Number of colonies counted
 
Number of cells seeded 
× PE /100% Survival fraction (SF)  = 
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CH3Cl/ MeOH (1:1) and separated by thin layer chromatography on a silica gel plate coated 
with 1 % K-oxalate, 2 mM EDTA in H2O/ CH3OH (3:2). The plates were developed in 
CHCl3/ CH3OH/ H2O/ NH4OH (45:35:8.5:1.5) and phosphorylated lipids were visualized by 
autoradiography. 
 
 
2.2.8 Real time PCR analysis  
 
2.2.8.1 RNA preparation 
  
At each indicated time point, medium was removed and the treated cells were lyzed directly 
in a culture plate using TRIzol reagent. Total RNA was prepared according to the 
manufacturer’s instruction. The RNA pellet was dissolved in RNAse-free water and the 
RNA concentration was determined by measuring the optical density (O.D.). The dissolved 
RNA was used for first-strand cDNA synthesis or stored at -80°C.  The O.D. at wavelength 
of 260 nm and a light pass of 1 cm correspond to approximately 40 μg/ml of RNA. The 
equation for calculating the RNA concentration is as following; 
 
 
 
 
 
 
 
2.2.8.2 First-strand cDNA synthesis 
 
After genomic DNA elimination, the RNA samples were reverse-transcribed using the 
QuantiTect reverse transcription kit, according to the manufacturer’s instruction.  The 
synthesized first-strand cDNA is ready for real time PCR analysis.  
RNA concentration (ug/ml) = OD 260 × 40 dilution factor 
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2.2.8.3 Quantitative Real time PCR  
 
Quantitative real time PCR was performed using the LightCycler FastStart Reaction Mix 
SYBR Green I. The primer pair for NBS1 amplification was 5’- CAG ACC TTA ATT CCT GAC TGT C - 
3’ as the forward primer and 5’- TTT ACA GTG GGT GCA TCT TGT G -3’ as the reverse primer. The 
primers for CCND1, FOS, SOS1, SOS2, and B2M amplification were purchased from 
Qiagen (unknown sequence). The relative expressions of the genes of interest were 
calculated by the ‘delta-delta Ct’ method [153]. The relative expression data were 
normalized by using B2M as a reference gene.   
 
 
2.2.9 Western blot analysis  
 
2.2.9.1 Whole cell lysate preparation 
 
At each indicated time point, the cells were detached with trypsin, collected by 
centrifugation at 300 ×g for 5 min. Whole cell lysates were prepared by suspending the cells 
in lysis buffer and incubating the suspension for 10 min on ice.  Cell lysates were collected 
after centrifugation at 16,000 ×g for 10 min. Protein concentration was determined using the 
Bradford reagent. Cells lysates were mixed with Laemmli’s buffer and then boiled at 95°C 
for 5 min.  
 
2.2.9.2 Nuclear and cytoplasmic extraction 
 
At each indicated time point, the cells were detached with trypsin, collected by 
centrifugation at 300 ×g for 5 min. Nuclear and cytoplasmic extracts were prepared using 
Pierce Nuclear and Cytoplasmic Extraction Reagent Kit (NE-PER) according to the 
manufacturer’s instruction. Cells extracts were mixed with Laemmli’s buffer and then boiled 
at 95°C for 5 min.  
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2.2.9.3 SDS polyacrylamide gel elctrophoresis and immunoblotting  
 
30 µg of protein from each sample were separated by electrophoresis in 8% to 12% SDS-
poly acrylamide gels. Proteins were then transferred to a blotting membrane and the 
membrane was incubated in blocking buffer containing 8% skim milk for 1 to 3 h at room 
temperature.  The membrane was washed 3 times with TBS-T and followed by incubation in 
Roti-block solution containing primary antibody overnight at 4°C. After washing 3 times 
with TBS-T, the membrane was incubated with horseradish peroxidase-labeled secondary 
antibody diluted in blocking buffer for 1 h.  The membrane was washed 3 times with TBS-T 
and then developed using chemiluminescence detection on X-ray films.   
 
 
2.2.10 Immunostaining and confocal microscopy 
 
To study ERK1/2 and Nbs1 subcellular localization by immunostaining, approximately 
3×105 cells were seeded into 4-well chamber slides and transfected with siRNA. After 24 h, 
cells were cultured in medium containing 0.2% FCS for 48 h, and medium was then 
replaced by fresh medium containing 10% FCS and 100 ng/ml of IGF-1.  After treatment, 
the cells were fixed for 15 min in 4% paraformaldehyde and permeabilized with 0.2% 
Triton-X-100 in PBS for 5 min. After blocking with 1% BSA for 60 min, the cells were 
probed with anti-Nbs1 and anti-Erk1/2 antibodies over night at 4°C, followed by incubation 
for 1 h at room temperature in the dark with fluorescence-labeled secondary antibodies Cy-
3, goat-anti-mouse IgG for Nbs1 and Alexa Fluor 488, goat anti-rabbit IgG for Erk1/2. The 
nuclei were stained with Hoechst 33342 and cover slips were mounted on slides with 
Vectashield.  
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3. RESULTS 
 
3.1 Suppression of endogenous Nbs1 levels in RPE cells by short interfering RNA 
 
To determine the functional role of NBS1 in cell cycle progression and cellular proliferation, 
small interfering RNAs (siRNAs) were used to specifically repress NBS1 levels in RPE 
cells.  Two oligonucleotide siRNA duplexes were used to target the human NBS1 mRNA 
while the non-targeting scramble siRNA (mock) duplexes were used as a negative control. 
The first NBS1 siRNA duplex (siNBS1) was used in all subsequent experiments while the 
second NBS1 Stealth siRNA duplex (si, 2) was used in some key experiments to rule out the 
off-target effect of siRNAs (result 3.8 and Fig. 33-37). The transfection reactions were 
performed by using siLentfect reagent. The NBS1 siRNA and scramble siRNA were used in 
a final concentration of 20 nM. After transient transfection, the expression level of 
endogenous NBS1 mRNA was determined by quantitative real-time PCR.  The result shown 
in Fig. 9 showed that the level of endogenous NBS1 mRNA in NBS1 siRNA-transfected 
cells was effectively repressed to less than 10% of the level in scramble siRNA-transfected 
cells as assessed at 24 to 90 h after transfection.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. NBS1 siRNA (siNBS1)-mediated down-regulation of endogenous NBS1 
mRNA. At 24, 48, 72, 90 h after transfection, the RPE  cells were harvested for mRNA 
extraction. The extracted mRNAs were reverse-transcribed and cDNA products from the 
reaction were used as a template for quantification of the NBS1 mRNA level in siNBS1-
transfected cells relative to scramble siRNA-transfected cells by quantitative real time 
PCR. B2M was used for normalization of the cDNA input in the reaction. This result is 
representative for two independent experiments. 
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In addition, the protein level of Nbs1 was also determined.  The whole cell lysates extracted 
from scramble and NBS1 siRNA-transfected cells were examined by Western blot analysis.   
A representative result is shown in Fig. 10A. In NBS1 siRNA-transfected cells, Nbs1 was 
almost completely absent at 48-90 h after transfection as detected by Western blot analysis.  
It has been reported that Mre11 and Rad50 are required for the stability of proteins 
component of the MRN complex. Deficiency of either Mre11 or Rad50 reduced the levels of 
the other two proteins of the MRN complex [156,157]. Therefore, the levels of Mre11 and 
Rad50 were analyzed in NBS1 siRNA-transfected cells compared to scramble siRNA-
transfected cells (Fig. 10B).  The results showed that the absence of Nbs1 did not affect the 
expression or the stability of its complex partners Mre11 and Rad50.  
 
 
 
 
 
 
 
 
    
 
 
 
 
 
Figure 10. The protein levels of Nbs1, Mre11, and Rad50 from the lysates of 
scramble siRNA-transfected cells (mock) and NBS1 siRNA-transfected cells 
(siNBS1). At the indicated time points after transfection, the RPE cells were harvested 
for whole cell lysate preparation. The whole cell lysates were analyzed by Western blot 
analysis. Antibodies against Nbs1, Mre11, or Rad50 identified Nbs1 as a 95 kD band, 
Mre11 as a 85 kD band, or Rad50 as a 153 kD band. Detection of actin was used as a 
loading control. (A) The levels of Nbs1 were determined at 48, 72, 90 h after 
transfection. (B) The levels of Nbs1 (left panel), Mre11 (middle panel), and Rad50 (right 
panel) were determined at 72 h after transfection. Each result is representative for two 
independent experiments.  
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3.2 The impact of Nbs1 on the regulation of cell cycle progression and proliferation 
of RPE cells 
 
3.2.1 The impact of Nbs1 on the regulation of cell cycle progression 
  
Flow cytometry allows to measure the DNA content of an individual cell, and reveals cell 
distribution over DNA content, which indicates the position of cells in the cell cycle. 
Therefore, flow cytometry was used to determine the cell cycle distribution in this study. 
DNA content distribution of a typical exponentially growing cell population is composed of 
two peaks of G1/G0 and G2/M phase cells and a valley of S phase cells. G2/M phase cells 
have twice the amount of DNA of G1/G0 phase cells, and S phase cells possess varying 
amounts of DNA between G1 and G2 cells. To demonstrate that NBS1 is essential for cell 
cycle progression, NBS1 siRNA or scramble siRNA-transfected cells were synchronized in 
G1/S phase by aphidicholin treatment. The cells were treated with 10 μg/ml aphidicolin for 
40 h and they were then released from the arrest by incubation in complete medium. The 
cells entering into S and G2/M phase were harvested at the indicated time points and the cell 
cycle distribution was monitored by flow cytometry.  
 
Representative results are shown in Fig. 11. After release from G1 arrest, 45% of the 
scramble siRNA-transfected cells progressed into S phase within 6 h and up to 58% of the 
cells reached G2/M phase within 28 h (Fig. 11, right panel). Delayed cell cycle progression 
was observed in NBS1 siRNA-transfected cells. When compared to scramble siRNA- 
transfected cells, suppression of endogenous NBS1 in RPE cells caused a 3.8 fold reduction 
in S phase cells and a significantly delayed progression to G2/M phase (2.5 fold reduction) 
as observed at 6 and 20 h after release from G1 arrest, respectively (Fig. 11, left panel).  
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Figure 11. Cell cycle analysis of scramble siRNA-transfected cells (mock) and NBS1 
siRNA-transfected cells (siNBS1). After transfection, RPE cells were cultivated for 40 h 
to allow siNBS1-mediated depletion of NBS1 expression.  The cells were synchronized at 
G1/S phase by treatment with 10 μg/ml aphidicolin for 24 h. Subsequently, the treated cells 
were released from the blockade and collected at the indicated time points for cell cycle 
analysis by flow cytometry. This result is representative for two independent experiments.  
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Cyclins are key regulators of the cell cycle progression. Periodical oscillation of cyclins is 
central to cell cycle regulation. Progression from G1 is initiated by cyclin D and followed by 
the expressions of cyclin E and cyclin A. To examine, whether delayed cell cycle 
progression in NBS1 siRNA-transfected cells is related to the disturbances of periodical 
oscillations of cyclins, the protein levels of cyclin E and cyclin A were determined.  Whole 
cell lysates, collected at 6, 20, and 28 h after release from G1 arrest, were determined by 
Western blot analysis. The results revealed the highest level of cyclin E in scramble siRNA-
transfected G1-arrested cells (time zero after release), which correlates with the largest 
population of cells in G1 phase. At the later time points, the level of cyclin E was 
significantly reduced due to the decline of cell numbers in G1.  In contrast, the level of 
cyclin E in G1 arrested cells was much lower in NBS1 siRNA-transfected as compared to 
scramble siRNA-transfected cells. Moreover, within the time of observation no reduction of 
the cyclin E level was observed in scramble siRNA-transfected cells after release from G1 
arrest (Fig. 12A). An increase in the amount of cyclin A was clearly observed at 20 and 28 h 
after release from G1 arrest in scramble siRNA-transfected cells (Fig. 12B). However, the 
level of cyclin A increased at a slower rate in NBS1 siRNA-transfected cells compared to 
scramble siRNA-transfected cells and reached the same level at 28 h after release. This 
result correlated with the delayed cell cycle progression of NBS1 siRNA-transfected cells 
that was observed from the cell cycle analysis.  
 
The disturbance in the periodic oscillation of cyclin E and delayed expression of cyclin A in 
NBS1 siRNA-transfected cells suggested that Nbs1 is involved in the regulation of cylin E 
and cyclin A expression.   
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Figure 12. The protein levels of cyclin E and cyclin A from lysates of scramble siRNA-
transfected cells (mock) and NBS1 siRNA-transfected cells (siNBS1) after release from 
G1/S arrest. After transfection, RPE cells were cultivated for 40 h to allow siNBS1-
mediated depletion of NBS1 expression.  The cells were synchronized at G1/S phase by 
treatment with 10 μg/ml aphidicolin for 24 h. Afterward the treated cells were released 
from the blockade and then collected at the indicated time points. The whole cell lysates 
were analyzed by Western blot analysis. Antibodies against cyclin E or cyclin A identified 
cyclin E as a 50 kD band (A), or cyclin A as a 60 kD band (B). Detection of actin was used 
as a loading control. Each result is representative for two independent experiments.  
 
 
3.2.2 The impact of Nbs1 on the proliferation capacity of RPE cells  
 
To investigate the consequences of NBS1 silencing on cell proliferation, the proliferation 
capacity of NBS1 siRNA-transfected cells was compared to scramble siRNA-transfected 
cells.  24 h after transfection with siRNAs, 10,000 cells were seeded into 30 mm dishes and 
cultivated for 96 h in medium containing 10% FCS. At the indicated time points, cells were 
trypsinized and the cell numbers were determined by using a particle counter and a 
microscope counting chamber.  The results showed that the cellular proliferation rate of 
NBS1 siRNA-transfected cells was significantly reduced by 60% (determined at day 4), as 
compared with scramble siRNA-transfected cells (Fig. 13).  
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The IGF-1 growth factor is a potent mitogen for cell proliferation in various cellular systems 
[158]. Thus, the impact of Nbs1 on proliferation of RPE cells after IGF-1 treatment was also 
determined. One day after NBS1 siRNA transfection, the cells were seeded into 6 well plates 
and cultured in medium containing 10% FCS in the presence or absence of IGF-1           
(100 ng/ml) for 1 to 4 days. The result showed a clearly enhanced cellular proliferation rate 
following IGF-1 treatment in scramble siRNA-transfected cells (~2 folds increased, as 
determined at day 4), while IGF-1-enhanced cellular proliferation rate was not observed in 
NBS1 siRNA-transfected cells (Fig. 13). This finding indicated that NBS1 is required for 
IGF-1-stimulated proliferation of RPE cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Cellular proliferation rate of scramble siRNA-transfected cells (mock) and 
NBS1 siRNA-transfected cells (siNBS1) under normal condition and in response to 
IGF-1 stimulation. One day after transfection, RPE cells were seeded into 6 well plates 
and incubated in medium containing 10% FCS either supplemented with or without IGF-1 
(100 ng/ml). Medium was changed every day. At the indicated time points, the cells were 
trypsinized and the cell number was determined in duplicate. The cell number is presented 
as the mean ± SD of three independent experiments. 
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3.3  The impact of Nbs1 on the downstream signaling cascades of the IGF1R 
 
3.3.1 The impact of Nbs1 on the PI3K/Akt cascade 
 
The previous findings indicated that Nbs1 has a role in IGF-1-induced cell proliferation. For 
further elucidation, the impact of Nbs1 on the initiation of signaling cascades downstream of 
the IGF-1 receptor was investigated. First, the activity of the PI3K/Akt, one of the key 
pathways downstream of the IGF-1 signaling, was investigated. 24 h after siRNAs 
transfection, cells were serum-starved for 24 h and then treated with or without IGF-1. The 
treated cells were collected at different time points after IGF-1 stimulation and cell lysates 
were prepared for the determination of PI3K activity (as described in 2.2.7). The result from 
the PI3K activity assay showed that under serume deprivation condition, the activity of 
PI3K was almost undetectable in scramble siRNA and NBS1 siRNA-transfected cells     
(Fig. 14). Upon IGF-1 stimulation, a strong increase of PI3K activity was observed in both 
scramble siRNA and NBS1 siRNA-transfected cells. Remarkably, the PI3K activity was 
higher in scramble siRNA-transfected cells than in NBS1 siRNA-transfected cells. 
 
Upon IGF1R stimulation, PI3K is activated which in turn activates Akt, a key downstream 
target of the cascade, by phosphorylating the serine residue 437 of Akt. Therefore, Western 
blot analysis was performed to determine the phosphorylation level of Akt.  The result 
showed that the basal level of phosphorylated Akt at serine 473 was lower in NBS1 siRNA-
transfected cells as compared to scramble siRNA-transfected cells while the total level of 
Akt was equivalent (Fig. 15A). Remarkably, in scramble siRNA-transfected cells, IGF-1 
triggered a strong increase of Akt phosphorylation which reached a maximum level        
(~40 fold) at 30 min after stimulation (Fig. 15B) and the phosphorylation could be blocked 
by the PI3K inhibitor wortmannin (Fig. 15C).  In contrast, IGF-1-induced phosphorylation 
of Akt was almost undetectable in NBS1 siRNA-transfected cells. These results revealed that 
NBS1 is involved in PI3K/Akt activation in response to IGF-1 treatment in RPE cells, which 
is consistent with recent findings showing an increase of PI3K activity and Akt 
phosphorylation upon over-expression of NBS1 in human hypopharyngeal cancer cell lines 
[159].  
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It had been reported that activation of PI3K/Akt upon mitogenic stimulation results in the 
phosphorylation of FOXO1, leading to nuclear exclusion and degradation of the FOXO1 
protein [160,161].  Therefore, the protein level of FOXO1 which is negatively regulated by 
the PI3K/Akt pathway was also determined in this study. The result showed that under 
serum deprivation condition, the level of FOXO1 was lower in scramble siRNA-tranfected 
cells than that of NBS1 siRNA-transfected cells (Fig. 15 D). A rapid decreasing of FOXO1 
level was clearly observed at 15 min and 30 min after IGF-1 treatment in scramble siRNA-
tranfected cells. In contrast, the level of FOXO1 was not altered in NBS1 siRNA-transfected 
cells after IGF-1 treatment. This result correlated well with a deteriorated activity of PI3K 
and Akt in NBS1 siRNA-transfected cells in response to IGF-1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. The impact of Nbs1 on the PI3K activity in response to IGF-1. 24 h after 
transfection, RPE cells were deprived of serum for 24 h. The serum deprived cells were 
subsequently treated with or without 100 ng/ml IGF-1 for 10 min. The treated cells were 
collected for cell lysate preparation. The PI3K activity was analyzed using p-Try 
immunoprecipitate of whole cell lysate extracted from scramble siRNA-transfected cells 
(mock), NBS1 siRNA-transfected cells (siNBS1). An immunoprecipitate generated with 
an antibody against the p85 subunit of PI3K served as positive control (P). The acitivity 
of PI3K is reflected by an intensity of the phosphoinositide phosphate (PIP) signal. This 
result is representative for two independent experiments.  
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Figure 15. The impact of Nbs1 on the activation of Akt in response to IGF-1. 24 h 
after transfection, RPE cells were deprived of serum for 24 h, treated with 100 ng/ml 
IGF-1 or pretreated with 10 μM wortmannin for 1 h. The treated cells were collected at  
different time points for protein extraction. The levels of Akt and p-Ser437-Akt in the 
protein extracts from scramble siRNA-transfected cells (mock) or NBS1 siRNA-
transfected cells (siNBS1) were determined by Western blot analysis. Antibodies against 
Akt or p-Ser437-Akt identified Akt and p-Ser437-Akt as a 60 kD band. The antibody 
against FOXO1 identified FOXO1 as a 80 kD band. Detection of actin was used as a 
loading control. (A) the levels of Akt and p-Ser437-Akt  under normal growth conditions, 
(B) the levels of p-Ser437-Akt upon IGF-1 stimulation after serum starvation, (C) the 
levels of p-Ser437-Akt upon IGF-1 stimulation after serum starvation with or without 
wortmanin (WT) pretreatment, and (D) the levels of FOXO1 upon IGF-1 stimulation 
after serum starvation. Each result is representative for two independent experiments.  
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3.3.2 The impact of Nbs1 on the activation of ERK1/2  
 
The activation of Ras/Raf/MEK/ERK is required for the biological activity of IGF-1 
regarding the regulation of cell proliferation, cell differentiation, and cell survival. Thus, I 
assessed whether NBS1 might be involved in Ras/Raf/MEK/ERK-mediated signaling in 
response to IGF-1 stimulation.  The activities of ERK1/2, the downstream effectors of the 
Ras/Raf/MEK/ERK cascade, were determined by measuring their phosphorylation status. 
IGF-1 triggered a strong increase of p-ERK1/2 levels in scramble siRNA-transfected cells 
which reached a maximum level (~13 fold) at 2 h after stimulation, while only slightly 
increased of pERK1/2 levels (~2 fold) were observed in NBS1 siRNA-transfected cells   
(Fig. 16). The total ERK1/2 protein levels in scramble siRNA-transfected cells and NBS1 
siRNA-transfected cells were equivalent and not altered following IGF-1 stimulation       
(Fig. 16).   
 
 
 
 
 
 
 
 
 
 
 
Figure 16. The impact of Nbs1 on the activation of ERK1/2 in response to IGF-1. One 
day after transfection, RPE cells were deprived of serum for 24 h, treated with 100 ng/ml 
IGF-1. The treated cells were collected at different time points for protein extraction. The 
levels of ERK1/2, and p-ERK in the protein extracted from scramble siRNA-transfected 
cells (mock) and NBS1 siRNA-transfected cells (siNBS1) were determined by Western blot 
analysis. Antibodies against ERK1/2 or p-ERK1/2 identified ERK1/2 or p-ERK1/2 as 42 
and 44 kD bands. Detection of actin was used as a loading control. This result is 
representative for two independent experiments.  
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Several signaling kinases participate in the transmission of signals via the ERK cascade. 
Therefore, the MEK1/2-specific inhibitor U0126 was applied to analyze whether the 
increased phosphorylation levels of ERK1/2 after IGF-1 stimulation occurred via the 
Ras/Raf/MEK pathway. The effects of U0126 on ERK1/2 phosphorylation and cellular 
proliferation after IGF-1 stimulation were analyzed. The results clearly showed that ERK1/2 
phosphorylations were abolished by U0126 (Fig. 17).  Additionally, the phosphorylation 
level of p90RSK, a downstream effector of ERK1/2, was also investigated. As the 
consequence of the deteriorated activity of ERK1/2 in NBS1 siRNA-transfected cells, the 
phosphorylation level of p90RSK at serine 380 which is phosphorylated by ERK1/2 upon 
growth factor stimulation was much lower in NBS1 siRNA-transfected cells as compared to 
scramble siRNA-transfected cells (Fig. 18). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. The effect of the MEK1/2 specific inhibitor U0126 on the IGF-1 induced 
phosphorylation of ERK1/2. One day after transfection, RPE cells were deprived of serum 
for 24 h, treated with 100 ng/ml IGF-1 or pretreated with 10 μM U0126 for 1 h. The treated 
cells were collected at different time points for protein extraction. The levels of ERK1/2, 
and p-ERK1/2 in the protein extracted from scramble siRNA-transfected cells (mock) and 
NBS1 siRNA-transfected cells (siNBS1) were determined by Western blot analysis. 
Antibodies against ERK1/2 and p-ERK1/2 identified ERK1/2 and p-ERK1/2 as 42 and 44 
kD bands. Detection of actin was used as a loading control. This result is representative for 
two independent experiments.  
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Figure 18. The impact of Nbs1 on the phosphorylation level of p90RSK upon IGF-1 
stimulation.  One day after transfection, RPE cells were deprived of serum for 24 h and 
treated with 100 ng/ml IGF-1. The treated cells were collected at different time points for 
protein extraction. The levels of p-p90RSK in the protein extracted from scramble siRNA-
transfected cells (mock) and NBS1 siRNA-transfected cells (siNBS1) were determined by 
Western blot analysis. Antibodies against p-p90RSK identified p-p90RSK as a 90 kD band. 
Detection of actin was used as a loading control. This result is representative for two 
independent experiments.  
 
 
Translocation of ERK1/2 from the cytoplasm into the nucleus is crucial for their biological 
activities [162,163]. Therefore, immunofluorescence staining was performed to monitor the 
subcellular distribution of ERK1/2 after IGF-1 stimulation in NBS1 siRNA-transfected cells 
versus scramble siRNA-transfected cells. Without stimulation, ERK1/2 localized mainly in 
the cytoplasm (Fig. 19A). Following IGF-1 stimulation, nuclear translocation of ERK1/2 
was clearly observed in scramble siRNA-transfected cells but not in NBS1 siRNA-
transfected cells, as determined at 1 h after IGF-1 treatment (Fig. 19B). Loss of nuclear 
translocation of ERK1/2 following IGF-1 stimulation in NBS1 siRNA-transfected cells 
correlated well with the low levels of ERK1/2 phosphorylation which were demonstrated by 
Western blot analysis.  
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Figure 19. Subcellular distribution of ERK1/2. The ERK1/2 subcellular localization in 
RPE cells was determined by immunostaining; about 3x105 cells were seeded into 4-wells 
chamber slides and transfected with scramble siRNA (mock) or NBS1 siRNA (siNBS1). 24 
h after transfection, the siRNA transfected cells were cultured in medium containing 0.2% 
FCS for 48 h. Subsequently, medium was replaced by complete fresh medium containing 
100 ng/ml IGF-I. After treatment, the cells were fixed and immunostained as described in 
materials and methods. (A) under serum deprivation condition, (B) after IGF-I treatment for 
60 minutes, (Nbs1) red, (ERK1/2) green, (nucleus) blue, and (white arrow) nucleus of a    
NBS1 depleted cell. Each result is representative for two independent experiments.  
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3.4 The impact of Nbs1 on IGF-1-induced cell proliferation via the 
Ras/Raf/MEK/ERK pathway 
 
3.4.1  The effect of the MEK1/2-specific inhibitor (U0126) on IGF-1-induced cell 
proliferation  
 
Activation of the Ras/Raf/MEK/ERK pathway has been shown to be important for IGF-1- 
stimulated cell proliferation in various cells types [10]. To examine whether the 
Ras/Raf/MEK/ERK pathway is involved in IGF-1-enhanced proliferation of RPE cells, the 
cellular proliferation activity was determined after inhibition of the Ras/Raf/MEK/ERK 
cascade by U0126. 24 h after transfection with siRNAs, the cells were seeded into 24-well 
plates, incubated for 4 h, and starved for 24 h. Then, the cells were pre-treated with vehicle 
alone or 10 μM U0126 and subsequently stimulated with medium containing 10% FCS and 
100 ng/ml IGF-1. Proliferation activities of the cells were measured by MTT assays at 48 h 
after treatment. The results are shown in Fig. 20; they indicated that the proliferation activity 
of scramble siRNA-transfected cells was strongly enhanced by IGF-1. In the presence of the 
inhibitor U0126, this induction was reduced by 50%.  In NBS1 siRNA-transfected cells, the 
proliferation activity enhanced by IGF-1 was 2-fold lower as compared to in scramble 
siRNA-transfected cells and additional treatment with the MEK inhibitor had no additional 
impact.   
 
 
 
 
 
 
 
 
 
 
Figure 20. Effect of the MEK1/2-specific inhibitor U0126 on the proliferation activities 
of scramble siRNA-transfected cells (mock) and NBS1 siRNA-transfected cells (siNBS1) 
after stimulation with IGF-1. One day after transfection with siRNAs, RPE cells were 
deprived of serum for 24 h, pretreated with 10 μM U0126 for 1 h and then stimulated with 
10% FCS containing 100 ng/ml IGF-1 for 48 h. or left unstimulated in medium without 
serum. Proliferation activity was measured by MTT assay. The result is shown as the mean   
± SD of n-fold increase in absorbance relative to the unstimulated serum deprived cells from 
three independent experiments.  
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3.4.2  The impact of Nbs1 on the IGF-1-induced cyclin D1 expression  
 
A disturbance of the IGF-1 signaling cascade was found to be the explanation for the 
impaired proliferation ability of NBS1 siRNA-transfected cells. Moreover, using the 
MEK1/2 specific inhibitor indicated that the Ras/Raf/MEK/ERK cascade, a downstream 
network of IGF-1, is involved. It has been well documented, that cyclin D1 is important for 
cell division by initiating the cell cycle re-entry. Its expression is strongly up-regulated upon 
growth factor stimulation through the Ras/Raf/MEK/ERK cascade via activation of the AP-1 
and Ets-1 transcription factors [123].  Thus, it can be assumed that induction of the cyclin 
D1 expression in response to IGF-1 is impaired in NBS1 siRNA-transfected cells. CCND1 
expression was determined by quantitative real time PCR. One day after siRNA transfection, 
the cells were grown under serum deprivation conditions for 2 days to synchronize cells in 
early G1 phase. After that, the cells were treated with 100 ng/ml IGF-1 and then collected at 
several time points for RNA and protein extraction. As expected, the levels of CCND1 
mRNA were low in scramble siRNA transfected cells and NBS1 siRNA-transfected cells 
under starvation conditions. Following IGF-1 stimulation, a strong induction of CCND1 
expression was clearly observed in scramble siRNA-transfected cells, whereas it was only 
slightly increased in NBS1 siRNA-transfected cells (Fig. 21).  
 
 
 
 
 
 
 
 
 
 
 
Figure 21. The expression of CCND1 upon IGF-1 stimulation in scramble siRNA-
transfected cells (mock) and NBS1 siRNA-transfected cells (siNBS1). At indicated time 
points upon IGF-1 treatment of RPE cells in the presence or absence of U0126, the mock 
and siNBS1 transfected cells were harvested for mRNA extraction. The extracted mRNA 
was reverse-transcribed and cDNA products from the reaction were used as a template for 
quantification of CCND1 mRNA by quantitative real time PCR. B2M was used for 
normalization of the cDNA input in the reaction. This result is representative for two 
independent experiments.  
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Comparable to the expression at mRNA level, Western blot analysis also revealed a low 
basal level of cyclin D1 protein in scramble siRNA-transfected cells, and it was nearly 
undetectable in NBS1 siRNA-transfected cells. The level of this protein was robustly 
increased after IGF-1 stimulation in scramble siRNA-transfected cells. However, the level of 
cyclin D1 was only slightly increased in NBS1 siRNA-transfected cells (Fig. 22A). 
Furthermore, in order to prove that NBS1 is involved in IGF-1-enhanced cyclin D1 
expressions in RPE cells via the Ras/Raf/MEK/MAPK cascade, cyclin D1 expression was 
determined after pretreatment with U0126 prior to IGF-1 stimulation. As expected, enhanced 
cyclin D1 expression at mRNA and protein level in scramble siRNA-transfected cells by 
IGF-1 was completely abolished by U0126 but this effect was not observed in siNBS1-
transfected cells (Fig. 21 and 22B). 
 
Taken together, these results indicate that impaired cell proliferation and delayed cell cycle 
progression as seen in NBS1 siRNA-transfected cells were likely due to the involvement of 
NBS1 in the Ras/Raf/MEK/ERK cascade, which at least in part induces cyclin D1 expression.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. The level of cylin D1 upon IGF-1 stimulation in lysates of scramble siRNA-
transfected cells (mock) and NBS1 siRNA-transfected cells (siNBS1). At indicated time 
points after IGF-1 treatment of RPE cells in presence or absence of U0126, scramble 
siRNA and NBS1 siRNA-transfected cells were harvested for whole cell lysate preparation. 
The level of cyclin D1 was determined by Western blot analysis. Antibody against cyclin 
D1 identified cyclin D1 as a 34 kD band. Detection of actin was used as a loading control. 
(A) The level of cyclin D1 at the indicated time points after IGF-1 stimulation. (B) The 
level of cyclin D1 at the indicated time points after U0126 pretreatment plus IGF-1 
stimulation. Each result is representative for two independent experiments. 
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3.4.3  The impact of Nbs1 on the IGF-1-induced c-Fos expression  
 
c-Fos belongs to the family of AP-1 transcription factors which are important regulators of  
the early transcriptional processes after extracellular stimulation. In response to IGF-1, AP-1 
is strongly up-regulated and activated by Ras/Raf/MEK/ERK resulting in the up-regulation 
of cyclin D1 expression [164]. Since induction of cyclin D1 expression upon IGF-1 
stimulation is diminished in NBS1 siRNA-transfected cells, expression of FOS was 
investigated both on the transcript and protein levels. RNA and protein were isolated from 
samples treated with IGF-1 alone or with IGF-1 plus U0126 pretreatment and subjected to 
quantitative real time PCR and Western blot analysis, respectively. The result shown in   
Fig. 23 for scramble siRNA-transfected cells, mRNA level of FOS was strongly increased to 
the maximum level of ~120 fold induction 30 min after IGF-1 stimulation and then declined 
rapidly within 1 h. U0126 pretreatment powerfully suppressed IGF-1-induced up-regulated 
FOS expression via inhibition of MEK1/2. In contrast to scramble siRNA-transfected cells, 
induction of FOS was much lower in NBS1 siRNA-transfected cells upon IGF-1 stimulation 
in the presence or absence of U0126. 
 
Results from Western blot analysis of c-Fos protein correlated with the FOS mRNA 
expression level (Fig. 24A).  The level of c-Fos protein increased within 2 h upon IGF-1 
stimulation in the scramble siRNA-transfected cells which was effectively abolished by   
pretreatment with U0126 (Fig. 24B). In contrast, only a slight increase in the level of c-Fos 
protein was observed in NBS1 siRNA-transfected cells.   
 
These findings confirmed the assumption that NBS1 is involved in the IGF-1 signaling 
pathway promoting cell cycle progression and cell proliferation, which is conferring its 
influences on the regulation of cyclin D1 expression via c-Fos through its role in 
Ras/Raf/MEK/ERK signaling. 
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Figure 23. The expression of FOS upon IGF-1 stimulation in scramble siRNA-
transfected cells (mock) and NBS1 siRNA-transfected cells (siNBS1).  At indicated time 
points upon IGF-1 treatment of RPE cells in the presence or absence of U0126, the mock and 
siNBS1 transfected cells were harvested for mRNA extraction. The extracted mRNA was 
reverse-transcribed and cDNA products from the reaction were used as a template for 
quantification of FOS mRNA by quantitative real time PCR. B2M was used for normalization 
of the cDNA input in the reaction. This result is representative for two independent 
experiments.  
 
 
 
 
 
 
 
 
 
 
 
Figure 24. The level of c-Fos upon IGF-1 stimulation from lysates of scramble siRNA-
transfected cells (mock) and NBS1 siRNA-transfected cells (siNBS1). At indicated time 
points upon IGF-1 treatment of RPE cells in the presence or absence of U0126, mock and 
siNBS1–transfected cells were harvested for whole cell lysate preparation. The protein level 
of c-Fos was determined by Western blot analysis. Antibody against c-Fos identified c-Fos as 
a 62 kD band. Detection of actin was used as a loading control. (A) The level of c-Fos at 
indicated time points after IGF-1 stimulation. (B) The level of c-Fos at indicated time points 
after U0126 pretreatment plus IGF-1 stimulation. Each result is representative for two 
independent experiments. The appearance of c-Fos at 5 h after U0126 pretretament plus IGF-
1 stimulation may result from reduction of the concentration or activity of U0126 in the 
medium.   
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3.5  The molecular mechanism of Nbs1 on the IGF-1 signaling cascade  
 
3.5.1   The influence of Nbs1 on the activation of c-Raf  
 
The results above indicated an impact of NBS1 on IGF-1-induced proliferation via the 
initiation of the signaling cascade upstream of ERK1/2, hence an active status of c-Raf was 
evaluated by Western blot analysis. IGF-1 triggered a strong increase of serine-338 
phosphorylation of c-Raf in scramble siRNA-transfected cells, which rapidly declined 
within 2 h after stimulation (Fig. 25). Notably, the phosphorylation level of c-Raf was much 
lower and hardly any IGF-1-induced activation could be detected in NBS1 siRNA-
transfected cells. These results suggested an early role for NBS1 upstream of c-Raf in IGF-1-
stimulated activation of the Ras/Raf/MEK/ERK signaling pathway.  
 
 
 
 
 
 
 
 
 
 
 
Figure 25. NBS1 is an upstream regulator of c-Raf. One day after transfection with 
scramble siRNA (mock) or NBS1 siRNA (siNBS1), RPE cells were deprived of serum for 
24 h and treated with 100 ng/ml IGF-1. The treated cells were collected at different time 
points for protein extraction. The level of p-c-Raf was determined by Western blot analysis. 
The antibody against p-c-Raf identified p-c-Raf as a 74 kD band. Detection of actin was 
used as a loading control. This result is representative for two independent experiments.  
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3.5.2  The influence of Nbs1 on the expression of SOS1, SOS2 and IGF1R 
 
Obviously, NBS1 influences the Ras/Raf/MEK/ERK cascade at a very early step upon 
receptor stimulation by IGF-1 treatment. Activation of the early factor Ras requires the 
action of guanine nucleotide exchange factors (like Sos1 and Sos2) to convert Ras from the 
inactive GDP-bound to the active GTP-bound form [165]. Therefore, I analyzed SOS1 and 
SOS2 expressions after NBS1 siRNA transfection by quantitative real time PCR. The results 
shown in Fig. 26 demonstrated that the amount of SOS1 and SOS2 transcripts of NBS1 
siRNA-transfected cells were decreased 4-5 fold as compared to scramble siRNA-
transfected cells. Reduced amounts of Sos1 and Sos2 were also detected on the protein level 
in NBS1 siRNA-transfected cells (Fig. 27). These reduced Sos1 and Sos2 levels could be a 
reason for the diminished activity of the Ras/Raf/MEK/ERK signaling pathway in NBS1 
siRNA-transfected cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Basal expression of SOS1 and SOS2 transcripts in scramble siRNA-
transfected cells (mock) and NBS1 siRNA-transfected cells (siNBS1). Relative amounts 
of SOS1 (A) and SOS2 (B) mRNAs were quantified in extracts of RPE NBS1 siRNA-
transfected cells and in that of scramble siRNA-transfected cells by quantitative RT-PCR. 
Samples were prepared at the indicated time points after transfection. Each result is 
representative for two independent experiments. 
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Figure 27. The basal levels of Sos1 and Sos2 from the lysates of scramble siRNA-
transfected cells (mock) and NBS1 siRNA-transfected cells (siNBS1). The RPE cells 
were transfected with NBS1 siRNA or scramble siRNAmock and collected at 48 h and 72 h 
after transfection for protein extraction. The levels of Sos1 (A) and Sos2 (B) were 
determined by Western blot analysis. Antibodies against Sos1 or Sos2 identified Sos1 or 
Sos2 as a 182 kD band. Detection of actin was used as a loading control. Each result is 
representative for two independent experiments. 
 
 
 
Activation of IGF1R is the proximal event of the Ras/Raf/MEK/ERK cascade. It was 
reported that IGF1R expression levels are suppressed in A-T cells and that the transcription 
activity of the IGF1R gene is dependent on ATM activity [166]. Since Nbs1 functions up-
stream and down-stream of ATM, it could be supposed that suppression of endogenous 
expression of NBS1 may also suppress the expression of IGF1R. Western blot analysis 
revealed that basal level of the IGF-1 receptor protein was significantly decreased in NBS1 
siRNA-transfected cells as compared to that in scramble siRNA-transfected cells (Fig. 28).  
 
Taken together, suppression of the basal expression levels of SOS1, SOS2, and IGF1R 
provided a strong explanation for the diminished activity of Ras/Raf/MEK/ERK signaling 
upon IGF-1 stimulation in NBS1 siRNA-transfected cells.  
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Figure 28. The basal levels of IGF1R (α-subunit) from the lysates of scramble siRNA-
transfected cells (mock) and NBS1 siRNA-transfected cells (siNBS1). The RPE cells 
were transfected with NBS1 siRNA or scramble siRNA and collected at 48 h and 72 h after 
transfection for protein extraction. The level of IGF1R (α-subunit) was determined by 
Western blot analysis. The antibody against IGF1R (α-subunit) identified IGF1R (α-
subunit) as a 130 kD band. Detection of actin was used as a loading control. This result is 
representative for two independent experiments.  
 
3.6    The influence of IGF-1 on the phosphorylation of Nbs1 
There are good evidences that Nbs1 is involved in the IGF-1 signaling pathway by 
influencing the expressions of SOS1, SOS2, and IGF1R. However, it is challenging to 
investigate the other possible roles of Nbs1, especially its function as an additional 
component of this signaling cascade. Phosphorylation of Nbs1 at serine residue 343 by 
ATM in response to radiation is required for its functions in signal transduction for DNA 
damage response. Since IGF-1 stimulation has been found to enhance kinase activity of 
ATM [167], it is interesting to investigate whether IGF-1 can also induce phosphorylation of 
Nbs1. Whole cell extracts from RPE cells upon IGF-1 stimulation were analyzed by 
Western blotting using a Nbs1 phospho-serine 343 antibody.  The results shown in Fig. 29A 
showed that the phosphorylation levels of Nbs1, under normal serum supplementation and 
serum deprivation, were very low and hardly detectable. However, phosphorylated Nbs1 
was remarkably increased at the earliest time point, 15 min after exposure of the cells to 
IGF-1. The accumulation of phosphorylated Nbs1 was sustained for several hours, the 
longest time points of observation was 5 h after IGF-1 treatment. The previous results 
demonstrated that NBS1 depletion caused diminished activity of the Ras/Raf/MEK/ERK 
cascade upon IGF-1 stimulation.  The MEK specific inhibitor U0126 had no effect on the 
level of phosphorylated Nbs1 (Fig. 29B). This finding clearly indicated that phosphorylation 
of Nbs1 was not transmitted via the MEK/ERK pathway.  
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Figure 29. The influence of IGF-1 on the phosphorylation of Nbs1. RPE cells were 
deprived of serum for 24 h, treated alone with 100 ng/ml IGF-1 (A) or treated with 100 
ng/ml IGF-1 plus 10 μM U0126 pretreatment (B). The treated cells were collected at 
different time points for protein extraction. The levels of p-Ser343-Nbs1 were determined 
by Western blot analysis. The antibody against p-Ser343-Nbs1 identified p-Ser343-Nbs1 as 
a 95 kD band. Detection of actin was used as a loading control. (nor) is referred to normal 
serum supplemented and (st) is referred to serum deprived. Each result is representative for 
two independent experiments. 
 
 
The finding that Nbs1 was phosphorylated rapidly upon IGF-1 stimulation raised the 
question for the possible mechanism of this event. Under normal circumstances, Nbs1 has 
been found to localize only in the nucleus, and how it is activated by receptor-mediated 
signaling is unknown. One possible explanation for the phosphorylation of Nbs1 upon IGF-
1 stimulation is the translocation of Nbs1 from the nucleus to cytoplasm. Therefore, 
immuno-fluorescence staining was performed for monitoring the subcellular distribution of 
Nbs1 in RPE cells. Nbs1 was found to localize only in the nucleus (Fig. 30A) and IGF-1 had 
no effect on the cellular distribution of Nbs1 (Fig. 30B). In addition, Western blot analysis 
of the nuclear and cytoplasmic fractions of RPE cells upon IGF-1 stimulation revealed the 
similar results. The Nbs1 protein was only detected in the nuclear fraction (Fig. 31, left 
panel) while it was not detectable in the cytoplasmic fraction during the time of observation 
(Fig. 31, right panel).   
 
These results demonstrated for the first time that IGF-1 induces phosphorylation of Nbs1, 
however the exact mechanism is unknown.  
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Figure 30. Subcellular localization of Nbs1. The subcellular localization of Nbs1 was 
determined by immunostaining. About 3x105 RPE cells were seeded into 4-wells chamber 
slides and cultivated for 48 h, afterward the cells were treated with or without 100 ng/ml 
IGF-1 for 1 h. After treatment, the cells were fixed and immunostained as described in 
material and method. (A) no treatment (B) 1 h after IGF-1 treatment , blue (nuclei) , red 
(Nbs1). Each result is representative for two independent experiments.  
 
 
 
 
 
 
 
 
 
 
Figure 31. Subcellular localization of Nbs1. The subcellular localization of Nbs1 was 
determined by Western blot analysis of nuclear (right panel) and cytoplasmic (left panel) 
extracts of RPE cells at the indicate time points after IGF-1 treatment. The antibody against 
Nbs1 identified Nbs1 as a 95 kD band. Detection of actin was used as a loading control. This 
result is representative for two independent experiments. 
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3.7 IGF-1 signaling cascade mediated cellular radio-resistance is associated with the 
increased radio-sensitivity of NBS1 siRNA-transfected cells  
 
The involvement of NBS1 in the IGF-1 signaling cascade on cell proliferation could explain 
the developmental defect and growth retardation phenotype in NBS patients. It also would 
be interesting to investigate a putative association between the IGF-1 signaling cascade-
related events and increased radio-sensitivity of NBS1 siRNA-transfected cells. Activation 
of IGF1R was found to possess the ability to confer clonogenic radio-resistance following 
ionizing radiation [168,169]. As the expression of IGF1R was strongly reduced in NBS1 
siRNA-transfected cells, it could be expected that this can contribute to enhanced radio-
sensitivity in these cells.  Therefore, clonogenic cell survival, as determined by colony 
forming assay, was used for measuring the radio-sensitivity of the cells. The scramble 
siRNA and NBS1 siRNA-transfected cells were pretreated with or without 100 ng/ml IGF-1 
for 1 h before gamma irradiation with the doses of 0, 3, 6, or 9 Gy. Of these, for the doses of 
3 and 6 Gy, NBS1 siRNA-transfected cells exhibited significantly enhanced radio-sensitivity 
as compared to scramble siRNA-transfected cells (Fig. 32A and B). For 9 Gy, the survival 
fractions between scramble siRNA and siNBS1-transfected cells were not significantly 
different because almost every cell was killed. Additional pretreatment with IGF-1 enhanced 
the survival fraction of scramble siRNA-transfected cells for the dose of 9 Gy by a factor of 
~5 as compared to no treatment (Fig. 32A and B). Notably, IGF-1 treatment in NBS1 
siRNA-transfected cells did not confer any significant increase in cell survival after 
irradiation.    
 
These results suggested that enhanced radio-sensitivity of NBS1 siRNA-transfected cells 
could at least partially derive from the disturbance of IGF-1 signaling.  
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Figure 32. Cellular radio-sensitivity of scramble siRNA-transfected cells (mock) and 
NBS1 siRNA-transfected cells (siNBS1) under normal conditions and in response to 
IGF-1 stimulation. One day after transfection of RPE cells with siRNA, cells were seeded 
into 6 well plates and incubated in medium containing 10% FCS. The cells were pre-treated 
with or without IGF-1 (100 ng/ml) for 1 h before gamma irradiation. Clonogenic survival 
of gamma-irradiated cells was determined at the tenth day after gamma irradiation. The 
dose survival curve shows a representative result from three independent experiments (A). 
The fold enhanced in cell survival after IGF-1 treatment was presented as the mean ± SD of  
the three independent experiments. 
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3.8  Validation of the key results by the second siRNA  
 
RNAi, mediated by siRNA, is widely used to silence gene expression. However, several 
reports have suggested that siRNA can regulate the expression of unintended targets (off-
target effect) [170,171]. To validate a confidence of the data from siRNA experiments in 
this study, the NBS1 Stealth siRNA was used as a second siRNA to target NBS1 mRNA and 
scramble Stealth siRNA was used as a negative control.  The transfection reactions were 
performed by using siLentfect reagent. The NBS1 Stealth siRNA and scramble Stealth 
siRNA were used in a final concentration of 20 nM. After transient transfection, the 
expression level of endogenous NBS1 mRNA was determined by quantitative real-time 
PCR.  The result showed that the level of endogenous NBS1 mRNA in NBS1 Stealth siRNA-
transfected cells  was effectively repressed to less than 10% of scramble Stealth siRNA-
transfected cells as assessed at 72 to 144 h after transfection (Fig. 33).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33.  NBS1 Stealth siRNA-mediated down-regulation of endogenous NBS1 
mRNA. At 24, 48, 72, 96, 144, and 192 h after transfection, the RPE cells were harvested 
for mRNA extraction. The extracted mRNA was reverse-transcribed and cDNA products 
from the reaction were used as a template for quantification of NBS1 mRNA in NBS1 
Stealth siRNA-transfected cells (si, 2) relative to scramble Stealth siRNA-transfected cells 
by quantitative real time PCR. B2M was used for normalization of the cDNA input in the 
reaction. This result is representative for two independent experiments.  
 
 
 
100
35
23
9 7 8
14
0
20
40
60
80
100
120
o h 24h 48 h 72 h 96 h 144 h 192 h
time after si, 2 transfection
re
la
tiv
e 
am
ou
nt
 o
f 
N
B
S
1
tra
ns
cr
ip
t 
re
la
tiv
e 
am
ou
nt
 o
f 
N
B
S
1
tra
ns
cr
ip
t 
re
la
tiv
e 
am
ou
nt
 o
f 
N
B
S
1
tra
ns
cr
ip
t 
Results 
 70
In addition, the protein level of Nbs1 was also determined.  The whole cell lysates extracted 
from scramble Stealth siRNA-transfected and NBS1 Stealth siRNA-transfected cells were 
examined by Western blot analysis. A representative result is shown in Fig. 34. In NBS1 
Stealth siRNA-transfected cells, the protein level of Nbs1 was almost completely absent at 
96 h to 192 h after transfection as detected by Western blot analysis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. The protein levels of Nbs1 from the lysates of scramble Stealth siRNA 
(mock, 2) and NBS1 Stealth siRNA (si, 2)-transfected cells. At indicated time points 
after transfection, the RPE cells were harvested for whole cell lysate preparation. The 
whole cell lysates were analyzed by Western blot analysis. The antibody against Nbs1, 
identified Nbs1 as a 95 kD band. Detection of actin was used as a loading control. (A) The 
levels of Nbs1 were determined at 48, 72, 96, 144, and 196 h after siRNA transfection. This 
result is representative for two independent experiments.  
 
 
The consequence of NBS1 silencing by NBS1 Stealth siRNA on the proliferation capacity of 
RPE cells was examined firstly. 72 h after transfection, the cellular proliferation rate of the 
cells were determined by using the same experimental conditions as described in 3.3.2. The 
similar results which were observed from NBS1 silencing by the first NBS1 siRNA duplex 
were demonstrated. Without IGF-1 treatment, the cellular proliferation rate of NBS1 Stealth 
siRNA-transfected cells was reduced by ~50%, as compared to scramble Stealth siRNA-
transfected cells (Fig. 35). IGF-1-enhanced cellular proliferation rate was clearly observed in 
scramble Stealth siRNA-transfected cells but was not observed in scramble Stealth siRNA-
transfected cells.  
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Figure 35. Cellular proliferation of scramble Stealth siRNA-transfected cells (mock, 2) 
and NBS1 Stealth siRNA-transfected cells (si, 2) under normal condition and in 
response to IGF-1 stimulation. 72 h after transfection, RPE cells were seeded into 6 well 
plates and incubated in medium containing 10% FCS either supplemented with or without 
IGF-1 (100 ng/ml). Medium was changed every day. At the indicated time points, the cells 
were trypsinized and the cell number was determined in duplicate. This result is 
representative for two independent experiments. 
 
 
Determination of the expression levels of SOS1, SOS2, and IGF1R were further repeated in 
order to rule out an off-target effect of the first siRNA duplex. The impact of NBS1 on the 
expression levels of SOS1, SOS2, and IGF1R was also demonstrated by application of NBS1 
Stealth siRNA. Reduced amounts of SOS1 and SOS2 transcripts and reduced amounts of 
Sos1, Sos2, and IGF1R proteins were demonstrated in NBS1 Stealth siRNA-transfected cells 
(Fig. 36-37).   
 
Taken together, these results confirmed that the observed phenotypes of RPE cells after 
suppression of endogenous NBS1 level by siRNAs are approved and that off-target effect of 
the siRNA duplexes can be ruled out.    
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Figure 36. Basal expression of SOS1 and SOS2 transcripts in scramble Stealth siRNA-
transfected cells and NBS1 Stealth siRNA-transfected cells. Relative amounts of SOS1 
(A) and SOS2 (B) transcripts were quantified in extracts of RPE NBS1 Stealth siRNA-
transfected cells (si, 2) and in that of scramble Stealth siRNA-transfected cells (mock, 2) by 
quantitative RT-PCR. Samples were prepared at indicated time points after transfection. 
Each result is representative for two independent experiments. 
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Figure 37. The basal levels of Sos1, Sos2, and IGF1R (α-subunit) from the lysates of 
scramble Stealth siRNA-transfected cells and NBS1 Stealth siRNA-transfected cells. 
The RPE cells were transfected with scramble Stealth siRNA (mock, 2) or NBS1 Stealth 
siRNA (si, 2) and collected at 96 and 144 h after transfection for protein extraction. The 
levels of Sos1 (A), Sos2 (B), and IGF1R (C) were determined by Western blot analysis. 
Antibodies against Sos1 or Sos2 identified Sos1 or Sos2 as a 182 kD band. The antibody 
against IGF1R (α-subunit) identified IGF1R (α-subunit) as a 130 kD band. Detection of 
actin was used as a loading control. Each result is representative for two independent 
experiments. 
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4.  DISCUSSION AND CONCLUSION 
 
4.1  Discussion 
 
4.1.1  Down-regulation of NBS1  
 
The experimental plan in this study was designed to analyze the function of Nbs1 without 
any impact of partial activities of Nbs1 truncated fragments that are expressed in NBS 
patient cell lines with the common 657del5 mutation. It has been proposed that the Nbs1 
truncated fragments may have partial activities in growth and development of mammals 
[51]. The significance of the truncated products had been observed in two knock-out mice 
which produce no truncated Nbs1 and die early in embryonic development while the other 
pair of knock-down mice which do produce truncated Nbs1 fragments are viable [51,172]. 
Before RNAi technology was invented, functional studies of Nbs1 had been done by using 
patient cell lines or knock-out technology. However, the disadvantage of using patient cell 
lines in addition to the interference from the partial function of truncated fragments is the 
variation of the genetic background of individual cells. For silencing the gene of interest, the 
knock out technology is frequently used in animal models, but this technique is 
cumbersome, time consuming, and it is not applicable in humans. During the past six years, 
the use of RNAi technology has been growing rapidly because it is a very effective post-
transcriptional gene silencing method and it is rather easy to perform. Most important is that 
RNAi engages an endogenous mechanism that exists in cells. For this reason, RNAi was 
employed to silence the expression of the NBS1 gene in this study.  
 
Recently, off-target effects that complicate the interpretation of data generated from siRNA-
mediated knock-down experiments have been reported [170,171]. To validate the data from 
siRNA experiments, two siRNA duplexes were independently used in this study. The first 
siRNA duplex (NBS1 siRNA) consists of two unmodified oligonucleotides while the second 
siRNA duplex (NBS1 stealth siRNA) consists of a chemically modified oligonucleotide 
duplex. The data presented here showed that the two different oligonucleotide siRNA 
duplexes effectively decreased the amount of NBS1 mRNA and Nbs1 protein. However, 
only the NBS1 siRNA was used for all experiments because it provides a rapid reduction of 
the Nbs1 protein and its effective knock-down period is more suitable. Using NBS1 siRNA,
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the amount of NBS1 mRNA was decreased effectively within 24 h after transfection while 
the Nbs1 protein was reduced by 24 h later. The disappearance of the Nbs1 protein occurs 
after the disappearance of NBS1 mRNA, because more time is needed for protein 
degradation. The down-regulations of NBS1 at mRNA and protein level were still effective 
up to 90 h, thus the further experiments were carried out within 48-90 after transfection of 
the cells with siRNA. To rule out a possible off-target effect, the determinations of cell 
proliferation capacity, expression levels of SOS1, SOS2, Sos1, Sos2, and IGF1R were 
repeated after suppression of endogenous NBS1 expression by NBS1 stealth siRNA. These 
are the key experiments which confirm that NBS1 influences IGF-1 signaling promoting cell 
proliferation by modulating the expressions of SOS1, SOS2, and IGF1R. Using NBS1 stealth 
siRNA, the amounts of NBS1 mRNA and Nbs1 protein were effectively decreased within 72 
and 96 h, respectively. Knock-down of NBS1 at mRNA and protein level by NBS1 stealth 
siRNA were still effective up to 144 h, thus the further experiments were carried out within 
96-144 h after transfection.  
 
It has been reported, that deficiency of Mre11 (in lymphoblastoid cell lines derived from 
ataxia-telangiectasia-like disorder patients) or Rad50 (in HCT116 and 293T cell lines after 
siRNA-mediated suppression of Rad50) causes a reduction of all protein components of the 
MRN complex [157,173]. This suggests, that either Rad50 or Mre11 or both are required for 
protein stability of the entire complex. The results in this report showed that in the absence 
of Nbs1, the levels of Mre11 and Rad50 are not reduced. Knock-down of NBS1 does not 
affect the protein levels of its complex partners, thus the RNAi approach is suitable for the 
functional study of a single protein, Nbs1. It has been reported, that Nbs1 is required for 
stimulation of DNA binding activity of the MRN complex and for the nuclease activity of 
Mre11/Rad50 [37]. In addition, Nbs1 is essential for nuclear localization and targeting of the 
MRN complex to the sites of DNA double strand breaks [32,44]. It should be considered 
that, although Nbs1 is not required for Mre11/Rad50 stability, the presence of Nbs1 is 
required for the activity of the complex [37].   
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4.1.2  NBS1 and cell cycle regulation 
 
The involvement of NBS1 in cell cycle progression of undamaged cells is clearly shown in 
this study. After release from G1 arrest, NBS1 siRNA-transfected cells showed slower 
progression from G1 phase to the next stages of the cell cycle as compared to scramble 
siRNA-transfected cells. Further investigations for the underlying mechanism of the delayed 
cell cycle progression in theses cells was focussed on the expression patterns of cyclins.  
The finding, that the periodical oscillations of cyclins E and A were disturbed in NBS1 
siRNA-transfected cells provides some evidence that Nbs1 influences cell cycle progression 
possibly at the beginning of G1 phase or, during G1/S phase transition.  
 
The accumulation of cyclin D1 is a key step for the cells to enter the cell cycle. Therefore, 
the expression pattern of cyclin D1 was determined in this study in order to clarify if NBS1 
is involved in the initiation step of cell cycle progression. Aphidicholin induces 
synchronization of the cells in early S phase by inhibiting the binding of 2’-
deoxynucleotides-5’-triphosphates to DNA polymerases α and δ [174], thus it can not be 
used for the analysis of cell cycle specific events at the initiation of G1 phase. A widely used 
model system to investigate cell proliferation, and thus G1 phase progression, is stimulation 
of serum-starved cells with growth factor [132]. Therefore, serum starvation, the standard 
approach to arrest the cells in G0 or early G1 phase, was used in this study. IGF-1 was 
selected for stimulating cell proliferation because this growth hormone is very important for 
pre-natal and post-natal growth and development [7,10]. The data presented here showed 
that the expression of cyclin D1 was very low in serum-starved cells. Upon IGF-1 
stimulation, the expression of cyclin D1 was rapidly increased in the scramble siRNA-
transfected cells but negligible in NBS1 siRNA-transfected cells. These results indicated the 
involvement of NBS1 in the initiation event of cell cycle re-entry probably by influencing 
the IGF-1 signaling-induced expression of the CCND1 gene.  
 
IGF-1 induces cell cycle progression and cell proliferation through different signaling 
pathways and different targets of cell cycle components dependent on the cell types. For 
example, in human osteosarcoma MG63 cells, IGF-1 stimulates CCND1 expression in an 
ERK1/2-dependent manner [175], but this effect is dependent on the PI3K/Akt signaling 
pathway in human BON neuroendocrine tumor cells [176]. In human intestinal smooth 
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muscle cells, effects of IGF-1 on proliferation are mediated jointly by the ERK1/2 and 
PI3K-dependent pathways that regulate cyclin D1 levels, and CDK4 activities. In this study, 
the identification of the pathway responsible for IGF-1-induced expression of cyclin D1 in 
RPE cells was performed by using a selective inhibitor. Application of the MEK1/2-specific 
inhibitor, U0126, completely abolished the induction of cyclin D1 and increased cellular 
proliferation induced by IGF-1. Therefore, it can be assumed that the Ras/Raf/MEK/ERK 
cascade is the major pathway for IGF-1-induced cell proliferation and cell cycle progression 
in RPE cells.  
 
It was reported, that PI3K/Akt and/or mTOR regulate cell growth and enhance cell 
proliferation by affecting CCND1 translation and cyclin D1 stabilization [177-179]. I also 
found that induction of Akt activity through PI3K by IGF-1 was impaired in NBS1 siRNA-
transfected cells. Since induction of CCND1 expression was completely abolished by 
MEK1/2 inhibition, it can be assumed that the PI3K/Akt cascade is not essential for the 
regulation of CCND1 expression in RPE cells. However, since the determination was carried 
out within 5 h after IGF-1 stimulation, it is possible that the Ras/Raf/MEK/ERK pathway 
up-regulates CCND1 expression during an early period of time after IGF-1 stimulation and 
that the other pathways, especially the PI3-K/Akt pathway, are involved in the regulation of 
cyclin D1 at later time points.  
 
ERK1 and ERK2 are the effector proteins of the Ras/Raf/MEK cascade. IGF-1 stimulation 
leads to phosphorylation of threonine and tyrosine residues within the activation loop of 
ERK1/2 [95]. Active ERKs phosphorylate targets in the cytoplasm and they translocate from 
the cytoplasm to the nucleus. Active ERK1/2 accumulate in the nucleus where they can 
directly phosphorylate many transcription factors involved in cell cycle regulation. The 
results clearly showed that NBS1 siRNA-transfected cells failed to response to IGF-1-
induced ERK1/2 activation which were demonstrated by the low levels of ERK1/2 
phophorylation and no accumulation of ERK1/2 in the nucleus after IGF-1 stimulation.  
 
The Ras/Raf/MEK/ERK cascade promotes transcription of the CCND1 gene via the 
activation of its promoter at the AP-1 site. The human CCND1 gene regulatory sequences 
contain two AP-1 binding sites [116]. Several AP-1 proteins including Jun and Fos bind to 
these sites and regulate CCND1 transcription [114,115]. The effect of the AP-1 transcription 
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factor on the activation of CCND1 depends on a complex composition and phosphorylation 
of Jun and Fos proteins.  In general, c-Jun is a target of the c-Jun N-terminal kinases (JNKs), 
and c-Fos is a target of ERKs. The proper regulation of c-Fos is important in many cellular 
processes including proliferation and differentiation  [102].  Control of cell proliferation by 
c-Fos is mainly mediated by its ability to regulate the expression of cell cycle regulators. For 
example, in response to growth factor stimulation, active ERK1/2 induce the 
phosphorylation of ternary complex factors especially Elk1 to induce transcription of the 
FOS gene [180]. c-Fos enters the nucleus immediately after translation. Accumulation and 
stabilization of c-Fos in the nucleus requires the phosphorylation at the C-terminal site by 
ERK1/2 and their down stream targets, ribosomal s6 kinases (RSKs), for  full stabilization 
of the c-Fos protein [181]. The accumulation of active c-Fos in the nucleus induces the 
transcription of many genes including Fos family member Fra1 a transcriptional activator of 
CCND1 promoter, leading to the induction of the CCND1 gene [164].  
 
The data reported here showed that FOS transcription peaks within minutes after growth 
factor stimulation in scramble siRNA-transfected cells. Remarkably, a big difference in the 
induction of the FOS expression between scramble siRNA-transfected cells and NBS1 
siRNA-transfected cells was clearly observed after IGF-1 stimulation. Specifically, it was 
confirmed by MEK inhibition that the Ras/Raf/MEK/ERK pathway regulates FOS 
expression. Taken together, these findings underline the role of Nbs1 in mitogenic signaling 
and cell proliferation. Obviously, Nbs1 is involved in the initiation event of cell cycle re-
entry through the Ras/Raf/MEK/ERK signaling cascade which regulates the expression of 
the CCND1 gene via Fos family members.  The data presented here propose a model for the 
function of Nbs1 upstream or at the level MEK1/2 (Fig. 38).   
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Figure 38. Scheme of a model for a putative regulation of the IGF-1 signaling cascade 
by Nbs1 (see more detail in the text). 
 
 
4.1.3 The influence of NBS1 on the expression of SOS1, SOS2 and IGF1R  
 
Data from this study suggested that NBS1 is mandatory at an early time point of IGF1R 
activation, since phosphorylation of c-Raf was already reduced in NBS1 siRNA-transfected 
cells after IGF-1 treatment. IGF-1-induced activation of the Ras/Raf/MEK/ERK cascade is 
mediated by the IGF1R-phosphorylated IRS-1 and Shc proteins, via interactions with Grb2 
and Sos [182] (Fig. 38). In response to signals induced by activated IGF1R, the guanine 
nucleotide exchange factors, Sos proteins, function as Ras activators [183]. Upon IGF1R 
activation, Sos is induced to form a complex with the adaptor protein Grb2. The Grb2-Sos 
complex interacts with activated IGF1R on the cytoplasmic side of the plasma membrane. 
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This allows the presentation of Sos to Ras, leading to the exchange of GDP for GTP and Ras 
activation [184].  Since Sos proteins are critical for Ras activation, the expressions of SOS1 
and SOS2 were quantified in NBS1 siRNA-transfected cells and scramble siRNA-transfected 
cells. A 4 to 5 fold reduction of SOS1 and SOS2 expressions in NBS1-depleted cells were 
demonstrated. Consistent with these results, a reduced amount of SOS2 expression in NBS1-
mutated cells was also shown by oligonucleotide microarray analysis of  the SV40-
transformed NBS fibroblast cell line [185]. Therefore, it can be suggested that IGF-1-
triggered Ras/Raf/MEK/ERK signaling is impaired in NBS1 siRNA-transfected cells due to 
NBS1-dependent expression of SOS1 and SOS2.  
 
Moreover, the data reported here also showed that NBS1 plays an important role in IGF1R 
protein expression. NBS1 down-regulated cells had low levels of IGF1R. In contrast to this, 
Watanabe et al. reported that there was no significant difference in IGF1R protein levels 
among normal cell lines, NBS patient cell lines, and NBS1-complemented NBS patient cell 
lines [186].  The contradiction may result from the use of different cell types and 
experimental strategies. The NBS cell lines which were used in the study mentioned above 
were SV40-transformed fibroblasts, derived from a patient harbouring a homozygous NBS1 
657del5 mutation. These patient cell lines express two truncated Nbs1 fragments which 
could be active in several functions, including regulation of IGF1R expression.  In the 
experimental system used in this study, full-length Nbs1 expression was repressed. Thus, the 
detected phenotypes represent the actual activity of Nbs1 and are not hidden by functions 
maintained by the expression of two partial Nbs1 fragments expressed in NBS patient cell 
lines with the common founder mutation 657del5 [17]. It should be considered that only the 
protein level of IGF1R was determined in this study. For further investigation, detection of 
IGF1R at mRNA level by quantitative real time PCR is suggested. 
 
The exact mechanism by which NBS1 influences the expression of the IGF1R protein 
remains to be elucidated. Interestingly, ATM controls IGF1R gene expression in a DNA 
damage response pathway via a mechanism involving the zinc-finger transcription factors 
Sp1 and WT1 [187].  In response to DNA damage, NBS1 was shown to act downstream and 
upstream of ATM [166]. Therefore, it might be possible that the impact of NBS1 on IGF1R 
expression resultes from its influence via ATM-related mechanisms. Two models can be 
proposed for the regulation for of IGF1R expression by Nbs1 (Fig.39). 
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Figure  39. Scheme of a putative role of Nbs1 in the regulation of IGF1R expression. 
Arrows with broken line represent the function of Nbs1 independent of ATM. The left 
model represents the function of Nbs1 upstream of ATM. The right model represents the 
function of Nbs1 downstream of ATM. Blue circles with a question mark represent 
unknown molecules.    
 
This report clearly demonstrated that NBS1 is involved in the IGF-1 signaling pathway by 
influencing the expression of SOS1, SOS2, and their proteins, and IGF1R. However, the 
finding that phosphorylation of Nbs1 can be induced by IGF-1 suggests an additional 
mechanism that may responsible for the diminished activity of downstream signaling 
cascades of IGF-1 in NBS1 down-regulated cells.  It has been shown that IGF1R signaling 
can modulate ATM kinase activity in response to ionizing radiation [167]. Moreover, Suzuki 
et al. also found that phosphorylation of ATM at both threonine and tyrosine residues is 
stimulated by IGF-1 [188].  These reports, together with the findings reported here, are 
likely to be an important link between IGF-1 and Nbs1. Serine 343 of Nbs1 is 
phosphorylated by ATM in response to ionizing radiation suggesting that Nbs1 functions 
downstream of ATM [26,27]. Therefore, it is possible that IGF-1-induced phosphorylation 
of Nbs1 is also mediated by ATM. However, there is also evidence that Nbs1 functions 
upstream of ATM [166]. Thus, it is also possible that IGF-1 signaling modulates activity of 
Nbs1 and then activated Nbs1 in turn activates ATM kinase activity leading again 
indistinguishable models (fig 40).  
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Figure 40. Scheme of the putative models for the phosphorylation of Nbs1 in 
response to IGF-1. Arrows with a broken line represent the phosphorylation of Nbs1 
independent of ATM. The left model represents the phosphorylation of Nbs1 up-stream of 
ATM phosphorylation. The right model represents the phosphorylation of Nbs1 down 
stream of ATM phosphorylation. Blue circles with a question mark represent unknown 
molecules.    
 
 
The molecular mechanism of NBS1 in IGF-1 signaling remains to be elucidated.  The data 
reported here showed that Nbs1 was mainly found in the nucleus, and that cytoplasmic 
translocation of Nbs1 after IGF-1 stimulation was not observed by immunofluorescence 
staining or Western blot analysis. Therefore, it is unlikely that Nbs1 has a direct interaction 
with the cytosol or membrane-localized components of the IGF-1 signaling.  In response to 
DNA damage, Nbs1 functions together with Mre11 and Rad50 in the DNA repair process, 
which requires their translocation from the cytoplasm to the nucleus to participate in DNA 
damage processing as a trimeric complex [1]. However, it is not known whether Nbs1 
functions independently or together with the Mre11/Rad50 complex in response to IGF-1. 
There is evidence that Nbs1 and Mre11/Rad50 may have an opposite role in the regulation 
of cell proliferation. Nbs1 over-expression increases cell proliferation [159], but over-
expression of Rad50 inhibits cellular proliferation [189]. One possible explanation for their 
opposite role can be seen in the ability of Nbs1 to modulate the nuclear and cytoplasmic 
pools of Mre11 and Rad50. In the absence of Nbs1, Mre11 and Rad50 may translocate 
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freely into the cytoplasm where they can interact with each other and with IGF-1 signaling 
components and thereby possibly inhibit the activation of the IGF-1 signaling cascade. 
Therefore, I hypothesize that in the presence of Nbs1, Mre11 and Rad50 are retained within 
the nucleus, resulting in the reduction of their concentration in cytoplasm, thus diminishing 
their inhibitory effect on the IGF-1 signaling cascade.   
  
 4.1.4 The disturbance of the IGF-1 signaling cascade causes increased radio-sensitivity 
of NBS1 siRNA-transfected cells 
In addition of being important for stimulation of cell proliferation, the IGFs system has been 
characterized as a cell survival factor in certain cells [16]. IGF-1 is a highly efficient anti-
apoptotic agent, not only because it has strong anti-apoptotic activities, but also because it 
protects cells from a variety of apoptotic stimuli, including osmotic stress [73], hypoxia 
[73], ionizing and non-ionizing radiation [190,191], and anti-cancer drugs [72].  Ionizing 
radiation is a potent inducer of cell killing by provoking damage to DNA and other cellular 
components in eukaryotic cells. Following radiation damage, several intracellular events are 
triggered. The plasma membrane receptors such as IGF1R, epidermal growth factor 
receptor, and Fas are activated [192-194]. The expression of genes encoding proteins that 
influence cell survival and cell death pathways such as Fas ligand, tumor necrosis factors, 
and p53 are changed [195-197].  The DNA  repair systems and cell cycle checkpoints that 
are crucial for maintaining the genomic integrity of cells damaged by radiation are activated 
[198,199].  Several studies indicate that IGF-1 signaling can modify cellular radio-
sensitivity. IGF1R overexpression mediates radio-resistance in breast cancer following 
radiotherapy [169].  Blocking of IGF1R activity by tyrosine kinase inhibitors or by anti-
IGF1R neutralizing antibodies was shown to increase radio-sensitivity of several types of 
human tumor cell lines [167,200,201].  The level of the IGF1R is often elevated in breast 
cancer cells and this characteristic has been assumed to be the cause for increased radio-
resistance and cancer recurrence in estrogen receptor-positive breast tumors [169,202]. In 
addition, the IGFs system may also prevent radiation-induced cell death by interfering with 
proteins involved in the repair or signaling of DNA lesions. It was found that ATM which 
plays an important role in the DNA damage response pathway is involved in the regulation 
of IGF1R activation and expression. Indeed, disturbed expression and activation of IGF1R 
have a major influence on the increased radio-sensitivity in ataxia telangiectasia patient cells 
[167,187,190].  
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In this study, the results from clonogenic cell survival upon gamma irradiation clearly 
showed that IGF-1 has a high potential to rescue gamma irradiation-induced cell death in 
RPE cells. The negligible effect of IGF-1 on the cell survival in NBS1 siRNA-transfected 
cells upon gamma irradiation indicated that increased radio-sensitivity in these cells may be 
the result, at least in part, from the disturbed IGF-1 signaling cascade. Evidence 
accumulated in several studies revealed a strong line between the IGFs system and cell 
killing after exposure to ionizing radiation [169,203-205]. However, the molecular 
mechanism how the IGFs system influences radio-resistance of the RPE cells is poorly 
understood. The IGFs system acts at different levels of the apoptotic machinery through 
different signaling pathways [16]. However, the PI3K/Akt cascade is considered as the 
canonical pathway involved in inhibition of apoptosis by IGF-1 [206]. Following IGF1R 
activation, PI3K is phosphorylated and activated, then in turn activates Akt. The activated 
Akt induces phosphorylation and then inactivation of pro-apoptotic factors, including the 
Bcl-2 family member Bad, members of the FOXO family, and caspases [16,207]. In 
addition, activation of Akt by IGF-1 has also been shown to increase expression of anti-
apoptotic factors, including   Bcl-x [208], and NF-κB [209].  The effects of IGFs on survival 
are also mediated by activation of the Ras/Raf/MEK/ERK pathway [207]. However, studies 
in most cell types indicated that the PI3K/Akt pathway was also functioning when 
Ras/Raf/MEK/ERK pathway was operating. It should be noted that both pathways may have 
either cooperative actions by objecting identical anti-apoptotic targets [210-212] or 
synergistic actions by activating different target molecules [213,214]. The data reported 
here, also showed that in response to IGF-1, activations of PI3K/Akt and 
Ras/Raf/MEK/ERK were impaired in RPE NBS1 siRNA-transfected cells. However, which 
pathway is responsible for the enhanced radio-sensitivity in this cell type remains to be 
further investigated.  
Furthermore, several studies reported that the anti-apoptotic effect of IGFs is independent of 
the PI3K/Akt or Ras/Raf/MEK/ERK cascades. The additional pathways are meditated 
through 14-3-3-dependent mitochondrial translocation of Raf and Nedd4. The presence of 
Raf and Nedd in the mitochondria maintains the mitochondrial integrity, and thus rescues 
cells from apoptosis [215].  Moreover, activation of IGF1R has been reported to rescue cells 
from apoptotic signal-regulated kinase 1 (ASK1)-induced cell death independently of PI3K 
[216]. ASK1 is a MAPK kinase involved in the activation of JNK and subsequent triggering 
of apoptosis by death-inducing receptors. Activation of IGF-1 signaling induces a complex 
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formation between activated IGF1R and ASK1 thereby antagonizing ASK1-induced 
apoptosis. Several studies also reported that additional pathways such as the p38 MAPK and 
JAK/STAT-3 may participate in the inhibition of apoptosis by IGF-1 [217,218].   
As mentioned above, the mechanism underlying enhanced radio-sensitivity of NBS1 siRNA 
-transfected cells needes to be clarified. Importantly, it should be considered that the 
increased radio-sensitivity of NBS1 siRNA-transfected cells may not be only influenced by 
the defect in the IGF-1 signaling cascade. A previous study from our group demonstrated 
that NBS1 mediates radio-resistance by suppressing the CD95 death receptor-dependent 
apoptotic pathway in lymphoblasts after gamma irradiation [155]. Therefore, NBS1 enables 
survival after gamma irradiation via several mechanisms and the rescue of cells after 
gamma-irradiation by IGF-1 is only one of them that is influenced by this gene.  
The summarizing models for the proposed roles of NBS1 in the regulation of cell 
proliferation, cell cycle progression, and cellular radio-sensitivity are shown in Fig. 41.   
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Figure 41. Scheme of the models for the novel roles of NBS1 in the regulation of cell 
proliferation, cell cycle progression and cellular radio-sensitivity. The right model; NBS1 
influences cell cycle proliferation and cell cycle progression via its influence on the 
expressions of IGF1R, SOS1, and SOS2, which are necessary for the proper activity of the 
IGF-1 signal transduction cascade that induces the expression of FOS and CCND1.            
The left model; the influence of NBS1 on IGF1R, SOS1, and SOS2 expressions is also 
important for the anti-apoptotic and survival activities of the IGF-1 signaling system after 
irradiation–induced damage. These activities are mainly mediated through the 
Ras/Raf/MEK/ERK and PI3K/Akt pathways. The question marks represent unknown 
molecules.    
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4.2  Conclusion  
In this study, the RNAi technique was employed to specifically repress NBS1 levels in RPE 
cells. This approach is effective for silencing NBS1 expression and suitable for the analysis 
of the functional role of Nbs1 without any impact of partial activities of Nbs1 truncated 
fragments that are expressed in NBS patient cell lines with the common 657del5 mutation 
and without any changing of protein levels of Mre11 and Rad50.  
The impact of NBS1 on cell cycle progression was clearly demonstrated in NBS1 siRNA 
transfected cells by the delayed cell cycle progression and the disturbances in periodical 
oscillation of cyclin E and cyclin A. The influences of NBS1 on the mitogen-stimulated cell 
proliferation and cell cycle re-entry were demonstrated in NBS1 siRNA-transfected cells by 
the failure of IGF-1 to increase cell proliferation and expression of CCND1. Furthermore, 
the Ras/Raf/MEK/ERK signaling cascade was identified as a major pathway that is 
responsible for IGF-1-induced cell proliferation and cell cycle progression in RPE cells. The 
critical points for this conclusion are considered from the phosphorylation levels and nuclear 
translocations of ERK1/2, the induction of FOS, and the application of the MEK1/2-specific 
inhibitor (U0126).  
The influences of NBS1 on the IGF1-1 signaling cascade were proven by the findings that 
the expression of IGF1R, SOS1, and SOS2 were suppressed in NBS1 siRNA-transfected 
cells. As a consequence of the reduced IGF1R expression in NBS1 siRNA-transfected cells, 
IGF-1 was unable to rescue the cells from radiation-induced cell death. Thus, diminished 
IGF-1 signaling contributes to enhanced radio-sensitivity of NBS1siRNA-transfected cells. 
In conclusion, this study provides evidences that NBS1 is involved in the promotion of cell 
proliferation, cell cycle progression, and cellular radio-resistance by influencing the IGF-1 
signaling cascade.  
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